{"content":"<li class=\"n-box-item date-title\" data-end=\"1518497999\" data-start=\"1518411600\" data-txt=\"Monday, December 23, 2019\">Monday, February 12, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3330373\" data-ts=\"1518480896\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABC\" target=\"_blank\">ABC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330373-amerisourcebergenplus-22-on-report-of-walgreens-buyout-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AmerisourceBergen +22% on report of Walgreens buyout talk</a></h4><ul>   <li>Drug distributor AmerisourceBergen (NYSE:<a href='https://seekingalpha.com/symbol/ABC' title='AmerisourceBergen Corporation'>ABC</a>) has <font color='green'>jumped 21.9%</font> in late trading after a <i>Wall Street Journal</i> report details a <a href=\"https://www.wsj.com/articles/walgreens-has-made-takeover-approach-to-amerisourcebergen-1518480542\" target=\"_blank\">takeover approach from Walgreens Boots Alliance</a> (NASDAQ:<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a>).</li>    <li>Through representatives, Walgreens made a high-level approach to Amerisource several weeks ago to talk about Walgreens taking the part of Amerisource that it doesn't already own.</li>    <li>There's no offer on the table, according to the report.</li>    <li>Walgreens has about 26% of Amerisource already, as well as a representative on the board.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330373\" data-linked=\"AmerisourceBergen +22% on report of Walgreens buyout talk\" data-tweet=\"$ABC $ABC $WBA - AmerisourceBergen +22% on report of Walgreens buyout talk https://seekingalpha.com/news/3330373-amerisourcebergenplus-22-on-report-of-walgreens-buyout-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3330373-amerisourcebergenplus-22-on-report-of-walgreens-buyout-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330371\" data-ts=\"1518480321\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HDNG\" target=\"_blank\">HDNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330371-hardinge-to-go-private-for-245m-sharesplus-6_2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hardinge to go private for $245M; shares +6.2%</a></h4><ul>   <li>Hardinge (NASDAQ:<a href='https://seekingalpha.com/symbol/HDNG' title='Hardinge, Inc.'>HDNG</a>) is <font color='green'>up 6.2%</font> after hours after <a href=\"https://seekingalpha.com/pr/17072538-hardinge-inc-acquired-privet-fund-management-llc-18_50-per-share-cash\" target=\"_blank\">agreeing to be acquired</a> by an affiliate of Privet Fund Management for $245M.</li>    <li>That's $18.50 per share in cash for the shares not already owned by Privet, a premium of 12.1% over the closing price on Nov. 1 (the last trading day before Privet said it was evaluating a potential transaction). It's an 8.3% premium over today's closing price.</li>    <li>The deal was negotiated by a Strategic Alternatives Committee that unanimously recommended the deal to the board.</li>    <li>Privet affiliates currently own about 10.46% of Hardinge and will vote in favor.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330371\" data-linked=\"Hardinge to go private for $245M; shares +6.2%\" data-tweet=\"$HDNG - Hardinge to go private for $245M; shares +6.2% https://seekingalpha.com/news/3330371-hardinge-to-go-private-for-245m-sharesplus-6_2?source=tweet\" data-url=\"https://seekingalpha.com/news/3330371-hardinge-to-go-private-for-245m-sharesplus-6_2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330367\" data-ts=\"1518476742\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HSIC\" target=\"_blank\">HSIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330367-ftc-alleges-dental-supply-companies-conspired-to-refuse-discounts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FTC alleges dental supply companies conspired to refuse discounts</a></h4><ul>     <li>The Federal Trade Commission <a href=\"https://www.ftc.gov/news-events/press-releases/2018/02/ftc-sues-dental-products-distributors-alleged-conspiracy-not\" target=\"_blank\">files a complaint</a> against the three largest U.S. dental supply companies - Henry Schein (NASDAQ:<a href='https://seekingalpha.com/symbol/HSIC' title='Henry Schein, Inc.'>HSIC</a>), Patterson Companies (NASDAQ:<a href='https://seekingalpha.com/symbol/PDCO' title='Patterson Companies Inc.'>PDCO</a>) and privately-held Banco Dental Supply - alleging they violated U.S. antitrust laws by conspiring to refuse discounts  to buying groups representing solo and small-group dental practices.</li><li>The FTC says the  three companies control more than 85% of distributor sales of dental products and services nationwide.</li><li>An administrative trial is scheduled for Oct. 12.</li><li><a href='https://seekingalpha.com/symbol/HSIC' title='Henry Schein, Inc.'>HSIC</a> <font color='red'>-6.5%</font>, <a href='https://seekingalpha.com/symbol/PDCO' title='Patterson Companies Inc.'>PDCO</a> <font color='red'>-5.8%</font> after-hours.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3330367\" data-linked=\"FTC alleges dental supply companies conspired to refuse discounts\" data-tweet=\"$HSIC $HSIC $PDCO - FTC alleges dental supply companies conspired to refuse discounts https://seekingalpha.com/news/3330367-ftc-alleges-dental-supply-companies-conspired-to-refuse-discounts?source=tweet\" data-url=\"https://seekingalpha.com/news/3330367-ftc-alleges-dental-supply-companies-conspired-to-refuse-discounts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330358\" data-ts=\"1518475110\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KDMN\" target=\"_blank\">KDMN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330358-after-hours-gainers-losers-2-12-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (2/12/2018)</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/KDMN' title='Kadmon Holdings'>KDMN</a> <font color='green'>+15.7%</font>. <a href='https://seekingalpha.com/symbol/VIPS' title='Vipshop Holdings'>VIPS</a> <font color='green'>+10.3%</font>. <a href='https://seekingalpha.com/symbol/VECO' title='Veeco Instruments Inc.'>VECO</a> <font color='green'>+6.6%</font>. <a href='https://seekingalpha.com/symbol/SREV' title='ServiceSource International, Inc.'>SREV</a> <font color='green'>+6.1%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='red'>-6.1%</font>. <a href='https://seekingalpha.com/symbol/G' title='Genpact Limited'>G</a> <font color='red'>-4.3%</font>. <a href='https://seekingalpha.com/symbol/NVTA' title='Invitae'>NVTA</a> <font color='red'>-4.3%</font>. <a href='https://seekingalpha.com/symbol/FENG' title='Phoenix New Media Limited'>FENG</a> <font color='red'>-3.5%</font>. <a href='https://seekingalpha.com/symbol/TER' title='Teradyne Inc.'>TER</a> <font color='red'>-2.0%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330358\" data-linked=\"After Hours Gainers / Losers (2/12/2018)\" data-tweet=\"$KDMN $KDMN $VIPS - After Hours Gainers / Losers (2/12/2018) https://seekingalpha.com/news/3330358-after-hours-gainers-losers-2-12-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3330358-after-hours-gainers-losers-2-12-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330352\" data-ts=\"1518474213\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GHL\" target=\"_blank\">GHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330352-greenhill-launches-dutch-auction-tender-shares-up-2_15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Greenhill launches Dutch auction tender; shares up 2.15%</a></h4><ul><li>The tender is for up to $110M worth of stock at a price no higher than $20.50, or less than $18.50. It's set to begin tomorrow and expire on March 14, unless extended.</li><li>After the tender, the remainder of the company's $285M repurchase program will be conducted through open market purchases or other means.</li><li><a href='https://seekingalpha.com/symbol/GHL' title='Greenhill & Co., Inc.'>GHL</a>&nbsp;<font color='green'>+2.15%</font>&nbsp;to $19.00 premarket</li><li>Source: <a href=\"https://seekingalpha.com/pr/17072500-greenhill-announces-terms-modified-dutch-auction-tender-offer\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3330352\" data-linked=\"Greenhill launches Dutch auction tender; shares up 2.15%\" data-tweet=\"$GHL - Greenhill launches Dutch auction tender; shares up 2.15% https://seekingalpha.com/news/3330352-greenhill-launches-dutch-auction-tender-shares-up-2_15?source=tweet\" data-url=\"https://seekingalpha.com/news/3330352-greenhill-launches-dutch-auction-tender-shares-up-2_15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330336\" data-ts=\"1518472155\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QLYS\" target=\"_blank\">QLYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330336-qualysplus-1_4-after-q4-beats-upside-q1-and-fy-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qualys +1.4% after Q4 beats, upside Q1 and FY guidance</a></h4><ul><li>        Qualys (NASDAQ:<a href='https://seekingalpha.com/symbol/QLYS' title='Qualys'>QLYS</a>) shares are&nbsp;<font color='green'>up 1.4%</font>&nbsp;aftermarket following Q4 results that beat EPS and revenue estimates.</li><li>               Upside Q1 guidance: Revenue, $63.4M to $64.1M (consensus: $62.78M); EPS, $0.32 to $0.34 (consensus: $0.26).&nbsp;</li><li>               Upside FY18 guidance: Revenue, $275.5M to $278.5M (consensus: $267.65M); EPS, $1.39 to $1.44 (consensus: $1.17).&nbsp;</li><li>               Repurchase program: Company announces a new $100M share repurchase program to offset dilution from employee grants and M&amp;A and $25M designated for venture capital investing.&nbsp;</li><li>           Earnings call scheduled for 5 PM Eastern Time with webcast available <a href=\"https://investor.qualys.com/events.cfm\" target=\"_blank\">here</a>.&nbsp;                      </li><li>               <a href=\"https://seekingalpha.com/pr/17072409-qualys-announces-fourth-quarter-full-year-2017-financial-results\" target=\"_blank\">Press release</a>&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3330308-qualys-beats-0_04-beats-revenue\" target=\"_blank\">Qualys beats by $0.04, beats on revenue</a> (Feb. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330336\" data-linked=\"Qualys +1.4% after Q4 beats, upside Q1 and FY guidance\" data-tweet=\"$QLYS - Qualys +1.4% after Q4 beats, upside Q1 and FY guidance https://seekingalpha.com/news/3330336-qualysplus-1_4-after-q4-beats-upside-q1-and-fy-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3330336-qualysplus-1_4-after-q4-beats-upside-q1-and-fy-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330332\" data-ts=\"1518471701\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBIO\" target=\"_blank\">CBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330332-catalyst-bio-readies-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catalyst Bio readies stock offering</a></h4><ul><li>Catalyst Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a>) <a href=\"https://seekingalpha.com/pr/17072454-catalyst-biosciences-announces-proposed-public-offering-common-stock\" target=\"_blank\">launches </a>a public offering of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330332\" data-linked=\"Catalyst Bio readies stock offering\" data-tweet=\"$CBIO - Catalyst Bio readies stock offering https://seekingalpha.com/news/3330332-catalyst-bio-readies-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3330332-catalyst-bio-readies-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330329\" data-ts=\"1518471546\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TYHT\" target=\"_blank\">TYHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330329-shineco-reports-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shineco reports Q2 results</a></h4><ul><li>Shineco (NASDAQ:<a href='https://seekingalpha.com/symbol/TYHT' title='Shineco, Inc.'>TYHT</a>): Q2 EPS of $0.17</li><li>Revenue of $14.13M (+25.9% Y/Y)</li><li>Shares <font color='green'>+27%</font>.</li><li><a href='https://seekingalpha.com/pr/17072437-shineco-inc-reports-second-quarter-2018-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3330329\" data-linked=\"Shineco reports Q2 results\" data-tweet=\"$TYHT - Shineco reports Q2 results https://seekingalpha.com/news/3330329-shineco-reports-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3330329-shineco-reports-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330320\" data-ts=\"1518471081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIPS\" target=\"_blank\">VIPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330320-vipshopplus-11_7-after-q4-growth-in-customers-and-average-revenues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vipshop +11.7% after Q4 with growth in customers and average revenues</a></h4><ul>   <li>Vipshop Holdings (NYSE:<a href='https://seekingalpha.com/symbol/VIPS' title='Vipshop Holdings'>VIPS</a>) is taking off after hours, <font color='green'>up 11.7%</font>, after <a href=\"https://seekingalpha.com/news/3330287-vipshop-holdings-beats-0_02-beats-revenue\" target=\"_blank\">Q4 earnings</a> with generally in-line revenues led to a profit beat, and the company guided high for Q1 revenues.</li>    <li>Total net revenue rose 27% in renminbi terms to 24.1B yuan on the back of both customer growth and average revenues.</li>    <li>Active customers rose 4% to 28.6M; total orders were up 27% to 104.2M.</li>    <li>Meanwhile, average revenue per customer was up 22%. Net income (non-GAAP) fell to 888.1M yuan from 970.3M.</li>    <li>The company expects \"further operating leverage\" in the long run from getting high-quality traffic via partnership with Tencent and JD.com.</li>    <li>For Q1, it's guiding to revenues of 19.1B-19.9B yuan -- a 20-25% growth rate and above consensus for 18.98B yuan.</li>    <li><a href=\"http://ir.vip.com/\" target=\"_blank\">Conference call</a> to come tomorrow at 8 a.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17072356-vipshop-reports-unaudited-fourth-quarter-full-year-2017-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3330320\" data-linked=\"Vipshop +11.7% after Q4 with growth in customers and average revenues\" data-tweet=\"$VIPS - Vipshop +11.7% after Q4 with growth in customers and average revenues https://seekingalpha.com/news/3330320-vipshopplus-11_7-after-q4-growth-in-customers-and-average-revenues?source=tweet\" data-url=\"https://seekingalpha.com/news/3330320-vipshopplus-11_7-after-q4-growth-in-customers-and-average-revenues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330318\" data-ts=\"1518471059\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VECO\" target=\"_blank\">VECO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330318-veeco-instrumentsplus-4_7-after-q4-earnings-upside-rev-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veeco Instruments +4.7% after Q4 earnings, upside rev. guidance</a></h4><ul><li>        Veeco Instruments (NASDAQ:<a href='https://seekingalpha.com/symbol/VECO' title='Veeco Instruments Inc.'>VECO</a>) shares are&nbsp;<font color='green'>up 4.7%&nbsp;</font>aftermarket following Q4 results that beat EPS estimates but missed on revenue.</li><li>               Q1 guidance: Revenue, $140M to $165M (consensus: $157.66M); EPS, -$0.04 to $0.14 (consensus: $0.01).&nbsp;</li><li>               Earnings call is scheduled for 5 PM Eastern Time with a webcast available <a href=\"http://ir.veeco.com/home/default.aspx\" target=\"_blank\">here</a>.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17072364-veeco-reports-fourth-quarter-fiscal-year-2017-financial-results\" target=\"_blank\">Press release</a>&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3330290-veeco-instruments-beats-0_10-misses-revenue\" target=\"_blank\">Veeco Instruments beats by $0.10, misses on revenue</a> (Feb. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330318\" data-linked=\"Veeco Instruments +4.7% after Q4 earnings, upside rev. guidance\" data-tweet=\"$VECO - Veeco Instruments +4.7% after Q4 earnings, upside rev. guidance https://seekingalpha.com/news/3330318-veeco-instrumentsplus-4_7-after-q4-earnings-upside-rev-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3330318-veeco-instrumentsplus-4_7-after-q4-earnings-upside-rev-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330313\" data-ts=\"1518470759\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKS\" target=\"_blank\">BKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330313-job-cuts-reported-barnes-noble\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Job cuts reported at Barnes &amp; Noble</a></h4><ul> <li>Sources tell CNBC that Barnes &amp; Noble (NYSE:<a href='https://seekingalpha.com/symbol/BKS' title='Barnes & Noble Inc'>BKS</a>) is <a href=\"https://www.cnbc.com/2018/02/12/barnes-noble-cuts-staff-after-dismal-holiday-season.html\" target=\"_blank\">laying off</a> workers after coming off a poor holiday season sales performance.</li> <li>The jobs cuts are reportedly at store level and at the corporate office.</li> <li>B&amp;N statement: \"Given our sales decline this holiday, we're adjusting staffing so that it meets the needs of our existing business and our customers. As the business improves, we'll adjust accordingly.\"</li> <li>Shares of Barnes &amp; Noble <font color='red'>fell 3.09%</font> to $4.70 today.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330313\" data-linked=\"Job cuts reported at Barnes &amp; Noble\" data-tweet=\"$BKS - Job cuts reported at Barnes &amp; Noble https://seekingalpha.com/news/3330313-job-cuts-reported-barnes-noble?source=tweet\" data-url=\"https://seekingalpha.com/news/3330313-job-cuts-reported-barnes-noble\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330307\" data-ts=\"1518470339\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMKR\" target=\"_blank\">AMKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330307-amkor-technologyplus-6_8-on-q4-beats-in-line-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amkor Technology +6.8% on Q4 beats, in-line guidance</a></h4><ul><li>        Amkor Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/AMKR' title='Amkor Technology, Inc.'>AMKR</a>) shares are&nbsp;<font color='green'>up 6.8%&nbsp;</font>aftermarket following Q4 results that beat EPS and revenue guidance.</li><li>               In-line Q1 guidance: Revenue, $1.02B (consensus: $1.02B); EPS, -$0.02 to $0.11 (consensus: $0.11); gross margin, 14% to 16%.&nbsp;</li><li>               Key metrics: Gross margin, 19.6%; cash from operating activities, $204M; FCF, $76M; cash and equivalents, $600M; total debt, $1.4B.&nbsp;</li><li>               Earnings call is scheduled for 5 PM Eastern Time with a webcast available <a href=\"https://amkor.com/\" target=\"_blank\">here</a>.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17072345-amkor-technology-reports-financial-results-fourth-quarter-full-year-2017\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3330283-amkor-technology-beats-0_06-beats-revenue\" target=\"_blank\">Amkor Technology beats by $0.06, beats on revenue</a> (Feb. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330307\" data-linked=\"Amkor Technology +6.8% on Q4 beats, in-line guidance\" data-tweet=\"$AMKR - Amkor Technology +6.8% on Q4 beats, in-line guidance https://seekingalpha.com/news/3330307-amkor-technologyplus-6_8-on-q4-beats-in-line-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3330307-amkor-technologyplus-6_8-on-q4-beats-in-line-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330302\" data-ts=\"1518469989\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RNG\" target=\"_blank\">RNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330302-ringcentralplus-8_7-revenues-grow-third-guidance-comes-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RingCentral +8.7% as revenues grow by a third, guidance comes high</a></h4><ul>   <li>RingCentral (NYSE:<a href='https://seekingalpha.com/symbol/RNG' title='RingCentral, Inc.'>RNG</a>) is <font color='green'>up 8.7%</font> after hours following <a href=\"https://seekingalpha.com/news/3330280-ringcentral-beats-0_01-beats-revenue\" target=\"_blank\">Q4 earnings</a> that beat on top and bottom lines with near-35% revenue growth.</li>    <li>Software subscriptions revenue grew 32% Y/Y to $129.7M, and annualized exit recurring software subscriptions also grew 32%, to $546.4M. RingCentral Office ARR was up 36%, to $466.2M.</li>    <li>A \"great year\" was \"led by our mid-market and enterprise business and further supported by continuing momentum from our channel partners. And we capped off the year with a record 15 deals with total contract value of more than $1M, up from 10 deals last quarter,&rdquo; said Chairman/CEO Vlad Shmunis.</li>    <li>The company had cash and equivalents of $181.2M at quarter's end, vs. the prior quarter's $172.3M.</li>    <li>For Q1, it's guiding to revenues of $144.5M-$146.5M (above consensus for $140.5M), non-GAAP operating margin of 7-7.6%, and EPS of $0.11-$0.13 (above consensus for $0.05).</li>    <li>For the full year, it's guiding to revenue of $629M-$639M (above consensus for $614M), operating margin of 7.8-8.2%, and EPS of $0.56-$0.60 (above expectations for $0.28).</li>    <li><a href=\"http://ir.ringcentral.com/\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>   <li><a href=\"https://seekingalpha.com/pr/17072332-ringcentral-announces-fourth-quarter-full-year-2017-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3330302\" data-linked=\"RingCentral +8.7% as revenues grow by a third, guidance comes high\" data-tweet=\"$RNG - RingCentral +8.7% as revenues grow by a third, guidance comes high https://seekingalpha.com/news/3330302-ringcentralplus-8_7-revenues-grow-third-guidance-comes-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3330302-ringcentralplus-8_7-revenues-grow-third-guidance-comes-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330292\" data-ts=\"1518469659\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFMD\" target=\"_blank\">AFMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330292-affimed-commences-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Affimed commences stock offering</a></h4><ul><li>Affimed N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a>) <a href=\"https://seekingalpha.com/pr/17072346-affimed-announces-proposed-public-offering-common-stock\" target=\"_blank\">launches </a>a public offering of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330292\" data-linked=\"Affimed commences stock offering\" data-tweet=\"$AFMD - Affimed commences stock offering https://seekingalpha.com/news/3330292-affimed-commences-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3330292-affimed-commences-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330287\" data-ts=\"1518469589\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIPS\" target=\"_blank\">VIPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330287-vipshop-holdings-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vipshop Holdings beats by $0.02, beats on revenue</a></h4><ul><li>Vipshop Holdings (NYSE:<a href='https://seekingalpha.com/symbol/VIPS' title='Vipshop Holdings'>VIPS</a>): Q4 EPS of $0.22 <font color='green'>beats by $0.02</font>.</li><li>Revenue of $3.7B (+23.3% Y/Y) <font color='green'>beats by $20M</font>.</li><li>Shares <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/pr/17072356-vipshop-reports-unaudited-fourth-quarter-full-year-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3330287\" data-linked=\"Vipshop Holdings beats by $0.02, beats on revenue\" data-tweet=\"$VIPS - Vipshop Holdings beats by $0.02, beats on revenue https://seekingalpha.com/news/3330287-vipshop-holdings-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3330287-vipshop-holdings-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330285\" data-ts=\"1518469548\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PACB\" target=\"_blank\">PACB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330285-pacific-biosciences-launches-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pacific Biosciences launches stock offering</a></h4><ul><li>Pacific Biosciences of California (NASDAQ:<a href='https://seekingalpha.com/symbol/PACB' title='Pacific Biosciences of California'>PACB</a>) <a href=\"https://seekingalpha.com/pr/17072339-pacific-biosciences-california-inc-announces-proposed-public-offering-common-stock\" target=\"_blank\">commences </a>a public offering of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330285\" data-linked=\"Pacific Biosciences launches stock offering\" data-tweet=\"$PACB - Pacific Biosciences launches stock offering https://seekingalpha.com/news/3330285-pacific-biosciences-launches-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3330285-pacific-biosciences-launches-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330276\" data-ts=\"1518468886\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRC\" target=\"_blank\">CRC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330276-california-resources-raised-to-outperform-imperial-capital\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">California Resources raised to Outperform at Imperial Capital</a></h4><ul>     <li>California Resources (<a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a> <font color='green'>+5.1%</font>) is <a href=\"https://www.streetinsider.com/Analyst+Comments/Imperial+Capital+Upgrades+California+Resources+%28CRC%29+to+Outperform/13794737.html\" target=\"_blank\">upgraded</a> to Outperform from In-Line with a $26 price target at Imperial Capital following <a href=\"https://seekingalpha.com/news/3329106-california-resources-announces-new-midstream-jv-equity-investment\" target=\"_blank\">last week's announcement</a> of a new midstream joint venture and equity investment.</li>     <li>CRC has discussed the potential of additional joint venture projects utilizing its sizable asset base, and Imperial believes the recent announcement adds  significant incremental capital that the company can either deploy on its assets or continue to work on improving its balance sheet and debt metrics; the firm thinks these funds can lead to significant future value for CRC.</li>     <li>Imperial sees last week's developments as further evidence of the value in CRC's asset base.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330276\" data-linked=\"California Resources raised to Outperform at Imperial Capital\" data-tweet=\"$CRC - California Resources raised to Outperform at Imperial Capital https://seekingalpha.com/news/3330276-california-resources-raised-to-outperform-imperial-capital?source=tweet\" data-url=\"https://seekingalpha.com/news/3330276-california-resources-raised-to-outperform-imperial-capital\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330273\" data-ts=\"1518467803\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HES\" target=\"_blank\">HES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330273-hessplus-5-amid-credit-suisse-upgrade-broad-energy-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hess +5% amid Credit Suisse upgrade, broad energy gains</a></h4><ul>     <li>Hess (<a href='https://seekingalpha.com/symbol/HES' title='Hess Corporation'>HES</a> <font color='green'>+5.2%</font>)&nbsp;is higher as Credit Suisse <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/02/11179276/credit-suisse-upgrades-hess-after-reaching-price-target\" target=\"_blank\">upgrades</a> shares to Neutral from Underperform with an unchanged $42 price target after <a href=\"https://seekingalpha.com/news/3330024-hess-fighting-activist-pressure-touts-long-term-approach-shareholders\" target=\"_blank\">tumbling ~20% over the last two weeks</a> amid lower than expected production guidance for 2018 and the general selloff in oil prices and stocks.</li>     <li>Credit Suisse sees three potential catalysts ahead to support Hess' stock: Exploration results in Guyana and success in tests could increase the 3.2B boe of gross resource discovered to date; activist investor Elliott Management could push the company to pursue shareholder friendly measures; and better than expected production with Enchilada platform is expected to be restored in June.</li>     <li>The stock's valuation now appears to be \"fair\" and the negative thesis has largely played out, analyst William&nbsp;Featherston writes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330273\" data-linked=\"Hess +5% amid Credit Suisse upgrade, broad energy gains\" data-tweet=\"$HES - Hess +5% amid Credit Suisse upgrade, broad energy gains https://seekingalpha.com/news/3330273-hessplus-5-amid-credit-suisse-upgrade-broad-energy-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3330273-hessplus-5-amid-credit-suisse-upgrade-broad-energy-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330269\" data-ts=\"1518467418\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCSA\" target=\"_blank\">CMCSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330269-fox-business-comcast-on-dojs-antitrust-radar-screen\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fox Business: Comcast on DOJ&#39;s antitrust &#39;radar screen&#39;</a></h4><ul>   <li>Comcast (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) has showed up on the Dept. of Justice's <a href=\"https://twitter.com/CGasparino/status/963144484883193856\" target=\"_blank\">antitrust \"radar screen,\"</a> Fox Business' Charlie Gasparino says, and could revisit the Comcast-NBCUniversal merger when a probationary period ends in the fall (and could monkey-wrench a <a href=\"https://seekingalpha.com/news/3330045-comcast-mulling-new-bid-fox-assets\" target=\"_blank\">Comcast topping bid</a> for Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='green'>+2.7%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='green'>+2.4%</font>) assets).</li>    <li>The DOJ will characterize the Comcast-NBCU deal as failing to help consumers as part of a larger argument in its opposition to a similar deal: AT&amp;T's (<a href=\"http://seekingalpha.com/symbol/T\" target=\"_blank\">T</a> <font color='green'>+1.2%</font>) $85B bid for Time Warner (<a href=\"http://seekingalpha.com/symbol/TWX\" target=\"_blank\">TWX</a> <font color='green'>+1.5%</font>), Gasparino says.</li>    <li>The government is set to go to trial against the AT&amp;T-Time Warner deal next month.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330269\" data-linked=\"Fox Business: Comcast on DOJ&#39;s antitrust &#39;radar screen&#39;\" data-tweet=\"$CMCSA $CMCSA $FOX - Fox Business: Comcast on DOJ&#39;s antitrust &#39;radar screen&#39; https://seekingalpha.com/news/3330269-fox-business-comcast-on-dojs-antitrust-radar-screen?source=tweet\" data-url=\"https://seekingalpha.com/news/3330269-fox-business-comcast-on-dojs-antitrust-radar-screen\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330268\" data-ts=\"1518466652\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PVOTF\" target=\"_blank\">PVOTF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330268-monetizing-ready-to-use-cannabis-technology-top-priority-for-pivot-pharma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Monetizing ready-to-use cannabis technology top priority for Pivot Pharma</a></h4><ul><li>In an&nbsp;<a href=\"https://seekingalpha.com/pr/17071336-pivot-pharmaceuticals-provides-corporate-update\" target=\"_blank\">update </a>to investors, Pivot Pharmaceuticals (<a href='https://seekingalpha.com/symbol/PVOTF' title='Pivot Pharmaceuticals Inc.'>OTCQB:PVOTF</a> <font color='red'>-4.2%</font>) says it expects to close its acquisition of ERS Holdings and its ready-to-use cannabis patents by month-end. Monetizing the ready-to-infuse-cannabis oil-to-powder technology is a top priority for the Vancouver-based biopharmaceutical firm.</li><li>It also expects to close its acquisition of Thrudermic's patented transdermal nanotechnology by month-end. The technology will be the basis for future transdermal cannabinoids.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330268\" data-linked=\"Monetizing ready-to-use cannabis technology top priority for Pivot Pharma\" data-tweet=\"$PVOTF - Monetizing ready-to-use cannabis technology top priority for Pivot Pharma https://seekingalpha.com/news/3330268-monetizing-ready-to-use-cannabis-technology-top-priority-for-pivot-pharma?source=tweet\" data-url=\"https://seekingalpha.com/news/3330268-monetizing-ready-to-use-cannabis-technology-top-priority-for-pivot-pharma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330267\" data-ts=\"1518466391\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLB\" target=\"_blank\">CLB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330267-core-labs-says-sec-ended-unaoil-probe-no-action-taken\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Core Labs says SEC has ended Unaoil probe with no action taken</a></h4><ul>     <li>Core Laboratories (<a href='https://seekingalpha.com/symbol/CLB' title='Core Laboratories'>CLB</a> <font color='green'>+1.9%</font>) <a href=\"https://www.sec.gov/Archives/edgar/data/1000229/000100022918000025/clb-20171231_10k.htm\" target=\"_blank\">discloses</a> the SEC has <a href=\"https://blogs.wsj.com/riskandcompliance/2018/02/12/core-labs-juniper-networks-report-end-of-fcpa-probes/\" target=\"_blank\">ended an investigation</a> into the company's interactions with Unaoil and does not intend to take action against it.</li>     <li>CLB said in 2016 it was cooperating with a Department of Justice inquiry into its interactions with Monaco-based Unaoil that the department and the U.K.&rsquo;s Serious Fraud Office have investigated; the DoJ previously said it had ended that probe, which involved possible violations of the Foreign Corrupt Practices Act, without taking action.</li>     <li>Several firms linked to Unaoil came under scrutiny by authorities in the U.S., U.K. and elsewhere following articles that alleged widespread bribery by Unaoil on behalf of several oil and gas companies.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330267\" data-linked=\"Core Labs says SEC has ended Unaoil probe with no action taken\" data-tweet=\"$CLB - Core Labs says SEC has ended Unaoil probe with no action taken https://seekingalpha.com/news/3330267-core-labs-says-sec-ended-unaoil-probe-no-action-taken?source=tweet\" data-url=\"https://seekingalpha.com/news/3330267-core-labs-says-sec-ended-unaoil-probe-no-action-taken\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330263\" data-ts=\"1518465413\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGE\" target=\"_blank\">TGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330263-tallgrass-energy-partners-upgraded-tallgrass-gp-downgraded-barclays\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tallgrass Energy Partners upgraded, Tallgrass GP downgraded at Barclays</a></h4><ul>     <li>Tallgrass Energy Partners (TEP <font color='green'>+5.3%</font>) is <a href=\"https://www.streetinsider.com/Analyst+Comments/Barclays+Upgrades+Tallgrass+Energy+Partners+%28TEP%29+to+Overweight/13794863.html\" target=\"_blank\">upgraded</a> to Overweight and Tallgrass Energy GP&nbsp;(<a href='https://seekingalpha.com/symbol/TEGP-OLD' title='Tallgrass Energy GP LP'>TEGP-OLD</a> <font color='red'>-0.9%</font>)&nbsp;is <a href=\"https://www.streetinsider.com/Analyst+Comments/Barclays+Downgrades+Tallgrass+Energy+GP%2C+LP+%28TEGP%29+to+Equalweight/13794864.html\" target=\"_blank\">downgraded</a> at Barclays, which thinks an acquisition of TEP by TEGP is the most likely scenario following <a href=\"https://seekingalpha.com/news/3329186-tallgrass-companies-announce-deals-evaluation-organizational-structure\" target=\"_blank\">last week's</a> merging of Tallgrass Development into TEGP (including the 25% interest in REX&nbsp;American&nbsp;Resources) and news that Tallgrass will further evaluate its organizational structure.</li>     <li>In its scenario, Barclays values TEP at $43/share and TEGP at $25.</li>     <li>Barclays believes it would be difficult to structure an incentive distribution rights buy-in deal that would not be dilutive to TEP, especially due to the divergence in share price performance following last week's news.</li>     <li>The firm also notes that, on the restructuring call last week, management said it would work toward making Tallgrass one entity where everybody is on equal footing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330263\" data-linked=\"Tallgrass Energy Partners upgraded, Tallgrass GP downgraded at Barclays\" data-tweet=\"$TGE $TGE $TEGP-OLD - Tallgrass Energy Partners upgraded, Tallgrass GP downgraded at Barclays https://seekingalpha.com/news/3330263-tallgrass-energy-partners-upgraded-tallgrass-gp-downgraded-barclays?source=tweet\" data-url=\"https://seekingalpha.com/news/3330263-tallgrass-energy-partners-upgraded-tallgrass-gp-downgraded-barclays\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330262\" data-ts=\"1518465355\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMBR\" target=\"_blank\">AMBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330262-technology-top-gainers-losers-of-2_55-pm-2-12-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2.55 pm (2/12/18)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AMBR' title='Amber Road, Inc.'>AMBR</a> <font color='green'>+38%</font>. <a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a> <font color='green'>+34%</font>. <a href='https://seekingalpha.com/symbol/CSRA' title='CSRA Inc.'>CSRA</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/EMAN' title='eMagin Corporation'>EMAN</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy Inc.'>ENPH</a> <font color='green'>+19%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/QUMU' title='Qumu Corporation'>QUMU</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/OHGI' title='One Horizon Group, Inc.'>OHGI</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/SPNS' title='Sapiens International Corporation N.V.'>SPNS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/RVLT' title='Revolution Lighting Technologies, Inc.'>RVLT</a> <font color='red'>-10%</font>. COGT <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330262\" data-linked=\"Technology - Top Gainers / Losers as of 2.55 pm (2/12/18)\" data-tweet=\"$AMBR $AMBR $FNJN - Technology - Top Gainers / Losers as of 2.55 pm (2/12/18) https://seekingalpha.com/news/3330262-technology-top-gainers-losers-of-2_55-pm-2-12-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3330262-technology-top-gainers-losers-of-2_55-pm-2-12-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330260\" data-ts=\"1518464092\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOX\" target=\"_blank\">FOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330260-fox-pledging-independent-sky-news-part-of-takeover-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fox pledging independent Sky News as part of takeover deal</a></h4><ul>   <li>Rupert Murdoch is looking to <a href=\"https://finance.yahoo.com/news/fox-commits-sky-news-independence-120342363.html\" target=\"_blank\">\"firewall\" Sky News</a> as part of regulatory sweeteners intended to close Fox's (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='green'>+2.4%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='green'>+2%</font>) $15.7B takeout of the rest of Sky (<a href=\"http://seekingalpha.com/symbol/SKYAY\" target=\"_blank\">SKYAY</a> <font color='green'>+0.7%</font>).</li>    <li>Fox would also continue funding the channel (which operates at a loss) for five years, along with creating a fully independent board to reduce Murdoch family influence.</li>    <li>Fox had previously pledged to build a Sky News board with a majority of independent directors.</li>    <li>The UK Competition and Markets Authority had put forward three solutions last month: insulating Sky News from Fox influence; divesting Sky News; or simply blocking the deal.</li>    <li>But Sky has warned that if the deal were blocked it might have to close Sky news entirely, removing the BBC's main British competitor in 24-hour news.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3330225-rosenblatt-talk-counter-bid-comcast-lends-fox-upside\" target=\"_blank\">Rosenblatt: Talk of counter-bid from Comcast lends Fox upside</a> (Feb. 12 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330260\" data-linked=\"Fox pledging independent Sky News as part of takeover deal\" data-tweet=\"$FOX $FOX $FOXA - Fox pledging independent Sky News as part of takeover deal https://seekingalpha.com/news/3330260-fox-pledging-independent-sky-news-part-of-takeover-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3330260-fox-pledging-independent-sky-news-part-of-takeover-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330259\" data-ts=\"1518463926\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BWP\" target=\"_blank\">BWP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330259-boardwalk-pipeline-sinks-to-two-year-low-after-disappointing-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boardwalk Pipeline sinks to two-year low after disappointing Q4</a></h4><ul>     <li>Boardwalk Pipeline Partners (<a href='https://seekingalpha.com/symbol/BWP' title='Boardwalk Pipeline Partners, LP'>BWP</a> <font color='red'>-1.7%</font>) tumbles to a two-year low as low as $11 as <a href=\"https://seekingalpha.com/news/3330062-boardwalk-pipeline-partners-misses-0_06-misses-revenue\" target=\"_blank\">Q4 earnings</a> fall to $0.33/share from $0.35 during the year-ago quarter and revenues also slip more than 4% Y/Y, with both lagging analyst expectations.</li>     <li>BWP says distributable cash flow of $110M for Q4 and $600M for the full year represented a respective 14% decrease and an 18% increase from $128M and $507M a year earlier; excluding the impact of the Flag City sale, distributable cash flow would have totaled $537M for FY 2017.</li>     <li>BWP says Q4 results were hurt by the restructuring of contracts with Southwestern Energy on its Fayetteville and Greenville laterals and lower revenues in storage and parking and lending.</li>     <li>Growth capex for the full year came in at $570.5M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330259\" data-linked=\"Boardwalk Pipeline sinks to two-year low after disappointing Q4\" data-tweet=\"$BWP - Boardwalk Pipeline sinks to two-year low after disappointing Q4 https://seekingalpha.com/news/3330259-boardwalk-pipeline-sinks-to-two-year-low-after-disappointing-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3330259-boardwalk-pipeline-sinks-to-two-year-low-after-disappointing-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330258\" data-ts=\"1518463805\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330258-moviepass-strikes-studio-and-exhibitor-deals\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MoviePass strikes studio and exhibitor deals</a></h4><ul> <li>MoviePass announces that it signed multiple contracts on both per-title       and slate-wide bases with several Hollywood studios and independent       distributors.</li><li>The new partnership cover more than 1K theater screens and several major studios.</li><li>The company says theaters and exhibitors that partner with MoviePass are using features       only available on the MoviePass platform to help drive consumers to       films and events.</li><li>Studios are utilizing the MoviePass platform for e-mail marketing, targeted push notification, custom premium title placement within the MoviePass application and other features based on individual MoviePass subscriber movie-going         behavior</li><li>Exhibitor benefits include priority theater placement in the MoviePass application and marketing opportunities within the MoviePass application.</li><li>\"Partnering with MoviePass allows us to provide a value option to a       segment of our customers that doesn&rsquo;t impact our traditional pricing       structure,\" Main Street Theaters exec&nbsp;Michael Barstow.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17071744-moviepass-closes-several-studio-exhibitor-deals\" target=\"_blank\">Press Release</a></li><li>Shares of Helios and Matheson are&nbsp;<font color='green'>up 5.44%</font>&nbsp;on the day.</li>        </ul><div class=\"tiny-share-widget\" data-id=\"3330258\" data-linked=\"MoviePass strikes studio and exhibitor deals\" data-tweet=\"MoviePass strikes studio and exhibitor deals https://seekingalpha.com/news/3330258-moviepass-strikes-studio-and-exhibitor-deals?source=tweet\" data-url=\"https://seekingalpha.com/news/3330258-moviepass-strikes-studio-and-exhibitor-deals\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330257\" data-ts=\"1518463160\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CERC\" target=\"_blank\">CERC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330257-cerecor-to-acquire-avadel-pharmaceuticals-pediatric-assets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cerecor to acquire Avadel Pharmaceutical&#39;s pediatric assets</a></h4><ul>     <li>Cerecor (<a href='https://seekingalpha.com/symbol/CERC' title='Cerecor'>CERC</a> <font color='green'>+8.5%</font>) has entered into definitive agreements with Avadel U.S. Holdings, Inc., and its subsidiaries, to purchase and acquire all rights to Avadel's marketed pediatric products.</li>     <li>The transaction is anticipated to close before Feb. 28 (2018).</li>     <li>The acquisition of these assets aligns with Cerecor's strategy to become a leading U.S. pediatric pharmaceutical company.</li>     <li>TTM net sales for the acquired products were ~$8M.</li>     <li>Under the terms of the asset purchase agreement, Cerecor will purchase Avadel's pediatric assets for nominal cash payment and will assume certain of Avadel's financial obligations to Deerfield CSF, LLC, which include a $15M loan due in Jan. 2021 and certain royalty obligations through Feb. 2026.</li>     <li><a href=\"https://seekingalpha.com/pr/17071867-cerecor-acquire-avadel-pharmaceuticals-pediatric-assets\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3330257\" data-linked=\"Cerecor to acquire Avadel Pharmaceutical&#39;s pediatric assets\" data-tweet=\"$CERC - Cerecor to acquire Avadel Pharmaceutical&#39;s pediatric assets https://seekingalpha.com/news/3330257-cerecor-to-acquire-avadel-pharmaceuticals-pediatric-assets?source=tweet\" data-url=\"https://seekingalpha.com/news/3330257-cerecor-to-acquire-avadel-pharmaceuticals-pediatric-assets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330256\" data-ts=\"1518462824\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RUN\" target=\"_blank\">RUN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330256-sunrunplus-13-credit-suisse-upgrades-sees-shares-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sunrun +13% as Credit Suisse upgrades, sees shares at $15</a></h4><ul>     <li>Sunrun (<a href='https://seekingalpha.com/symbol/RUN' title='Sunrun'>RUN</a> <font color='green'>+12.7%</font>) sizzles as Credit Suisse initiates coverage with an <a href=\"https://www.bloomberg.com/news/articles/2018-02-12/sunrun-soars-as-credit-suisse-says-company-may-triple-in-value\" target=\"_blank\">Outperform rating</a> and $15 price target, nearly triple Friday's closing share price.</li>     <li>RUN will &ldquo;continue to gain market share in the residential solar market bolstered by a multi-channel approach, access to financing and focus on value creation,\" analyst Michael Weinstein writes.</li>     <li>Weinstein views RUN as the leader in rooftop solar and finds valuation attractive at current levels.</li>     <li>At the same time, the firm initiates First Solar (<a href='https://seekingalpha.com/symbol/FSLR' title='First Solar, Inc.'>FSLR</a> <font color='green'>+2.1%</font>) at Underperform with a $55 price target, saying the company is successfully transitioning to Series 6 technology while maintaining a healthy balance sheet, but the stock's 111% rise since May 2017 means the impact of the new solar import tariffs already are priced in.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330256\" data-linked=\"Sunrun +13% as Credit Suisse upgrades, sees shares at $15\" data-tweet=\"$RUN $RUN $FSLR - Sunrun +13% as Credit Suisse upgrades, sees shares at $15 https://seekingalpha.com/news/3330256-sunrunplus-13-credit-suisse-upgrades-sees-shares-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3330256-sunrunplus-13-credit-suisse-upgrades-sees-shares-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330255\" data-ts=\"1518462091\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGG-OLD\" target=\"_blank\">CGG-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330255-energy-materials-top-gainers-losers-of-2-00-pm-2-12-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm (2/12/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/NOG' title='Northern Oil & Gas, Inc'>NOG</a> <font color='green'>+16%</font>. EXXI <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/LLEX' title='Lilis Energy, Inc.'>LLEX</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/HOS' title='Hornbeck Offshore Services, Inc.'>HOS</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TORM' title='TOR Minerals International Inc'>TORM</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/BRN' title='Barnwell Industries, Inc'>BRN</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/CDXC' title='ChromaDex Inc.'>CDXC</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330255\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm (2/12/2018)\" data-tweet=\"$CGG-OLD $CGG-OLD $NOG - Energy/Materials - Top Gainers / Losers as of 2:00 pm (2/12/2018) https://seekingalpha.com/news/3330255-energy-materials-top-gainers-losers-of-2-00-pm-2-12-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3330255-energy-materials-top-gainers-losers-of-2-00-pm-2-12-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330253\" data-ts=\"1518461994\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCRX\" target=\"_blank\">PCRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330253-fda-ad-com-this-week-for-paciras-exparel\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA Ad Com this week for Pacira&#39;s Exparel</a></h4><ul><li>The FDA's Anesthetic and Analgesic Drug Products Advisory Committee will <a href=\"https://www.fda.gov/AdvisoryCommittees/Calendar/ucm592118.htm\" target=\"_blank\">meet </a>on February 14 &amp; 15 to discuss Pacira Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/PCRX' title='Pacira Pharmaceuticals, Inc.'>PCRX</a> <font color='red'>-2.1%</font>) New Drug Application seeking approval for EXPAREL (bupivacaine liposomal injectable solution) for local and regional anesthesia.</li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM596312.pdf\" target=\"_blank\">FDA briefing doc&nbsp;</a></li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM596313.pdf\" target=\"_blank\">Errata to FDA briefing doc</a></li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM596314.pdf\" target=\"_blank\">Company briefing doc&nbsp;</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3330253\" data-linked=\"FDA Ad Com this week for Pacira&#39;s Exparel\" data-tweet=\"$PCRX - FDA Ad Com this week for Pacira&#39;s Exparel https://seekingalpha.com/news/3330253-fda-ad-com-this-week-for-paciras-exparel?source=tweet\" data-url=\"https://seekingalpha.com/news/3330253-fda-ad-com-this-week-for-paciras-exparel\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330251\" data-ts=\"1518461843\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INTU\" target=\"_blank\">INTU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330251-deutsche-bank-raises-intuit-target-to-21-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche Bank raises Intuit target to 21% upside</a></h4><ul><li>        Deutsche Bank <a href=\"https://www.streetinsider.com/Analyst+Comments/Intuit+%28INTU%29+PT+Raised+to+%24190+at+Deutsche+Bank/13795054.html\" target=\"_blank\">maintains</a> a Buy rating and raises its Intuit (NASDAQ:<a href='https://seekingalpha.com/symbol/INTU' title='Intuit Inc.'>INTU</a>) price target by $10 to $190, a 21% upside on Friday&rsquo;s close. &nbsp;</li><li>        Latest analyst <a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=INTU:NSQ\" target=\"_blank\">recommendations</a>: 7 Buy, 2 Outperform, 12 Hold, and 2 Underperform.</li><li>               Median price target: $166.50.&nbsp;</li><li>               Intuit shares are&nbsp;<font color='green'>up 1.4%</font>&nbsp;to $159.28.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3330251\" data-linked=\"Deutsche Bank raises Intuit target to 21% upside\" data-tweet=\"$INTU - Deutsche Bank raises Intuit target to 21% upside https://seekingalpha.com/news/3330251-deutsche-bank-raises-intuit-target-to-21-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3330251-deutsche-bank-raises-intuit-target-to-21-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330250\" data-ts=\"1518461838\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APRN\" target=\"_blank\">APRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330250-blue-apron-heats-up-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blue Apron heats up ahead of earnings</a></h4><ul> <li>Blue Apron (NYSE:<a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a>) investors need to buckle tight for a wild ride tomorrow morning after the online meal kit company reports Q4 earnings.</li> <li>Bloomberg reports that options trading on the stock implies a 22% move up or down.</li> <li>Count Needham in on the side expecting Blue Apron to slightly top estimates. The firm expects to see Blue Apron report Q4 EBITDA of -$24.5M vs. -$25.8M consensus.</li> <li>New Blue Apron CEO Brad Dickerson's update on the company's New Jersey operations will also be crucial in determing positive or negative sentiment after the print.</li> <li>Shares of Blue Apron are <font color='green'>up 2.15%</font> on the day to $3.33 vs. a 52-week trading range of $2.94 to $11.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330250\" data-linked=\"Blue Apron heats up ahead of earnings\" data-tweet=\"$APRN - Blue Apron heats up ahead of earnings https://seekingalpha.com/news/3330250-blue-apron-heats-up-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3330250-blue-apron-heats-up-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330378\" data-ts=\"1518461087\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENPH\" target=\"_blank\">ENPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330378-enphase-energyplus-16-on-panasonic-ac-module-partnership\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Enphase Energy +16% on Panasonic AC module partnership</a></h4><ul>     <li>Enphase Energy (<a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy Inc.'>ENPH</a> <font color='green'>+16.2%</font>) soars after Panasonic (<a href='https://seekingalpha.com/symbol/PCRFY' title='Panasonic Corp. ADR'>OTCPK:PCRFY</a>) announces a strategic partnership with the company for the <a href=\"https://seekingalpha.com/pr/17071868-panasonic-enphase-energy-announce-strategic-partnership-high-efficiency-ac-modules\" target=\"_blank\">development of high efficiency AC modules</a>.</li>     <li>Panasonic says ENPH's new IQ 7X microinverter offers compatibility with its HIT solar modules and will be made available to distributors and installers in North America beginning in May.</li><li>Panasonic's N series PV modules are \"an ideal partner for the Enphase IQ 7X Microinverter,\" says Panasonic Residential Solar's group manager.  \"With a unique heterojunction technology and advanced bifacial cells,  these high efficiency panels offer homeowners state-of-the-art features  and maximum solar production.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330378\" data-linked=\"Enphase Energy +16% on Panasonic AC module partnership\" data-tweet=\"$ENPH $ENPH $PCRFY - Enphase Energy +16% on Panasonic AC module partnership https://seekingalpha.com/news/3330378-enphase-energyplus-16-on-panasonic-ac-module-partnership?source=tweet\" data-url=\"https://seekingalpha.com/news/3330378-enphase-energyplus-16-on-panasonic-ac-module-partnership\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330248\" data-ts=\"1518460997\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVMXY\" target=\"_blank\">AVMXY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330248-fda-signs-off-on-expanded-compassionate-use-for-avita-meds-skin-cell-harvesting-device-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA signs off on expanded compassionate use for Avita Med&#39;s skin cell harvesting device; shares up 12%</a></h4><ul><li>Thinly traded nano cap AVITA Medical (<a href='https://seekingalpha.com/symbol/AVMXY' title='Avita Medical Ltd. ADR'>OTCQX:AVMXY</a> <font color='green'>+11.7%</font>) is up on triple normal volume, albeit on turnover of only 92K shares, in response to its <a href=\"https://seekingalpha.com/pr/17071288-avita-medical-announces-fda-approval-expansion-recell-compassionate-use-program-life\" target=\"_blank\">announcement</a> that the FDA has OK'd another compassionate use expansion for its RECELL Autologous Cell Harvesting Device. Under the expanded protocol, 20 additional patients (up to a total of 88) with life-threatening injuries may be treated with RECELL. 64 patients have been treated to date.</li><li>RECELL is a regenerative medical device used to facilitate skin regeneration while reducing the amount of skin harvested at the time of surgery.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330248\" data-linked=\"FDA signs off on expanded compassionate use for Avita Med&#39;s skin cell harvesting device; shares up 12%\" data-tweet=\"$AVMXY $RCEL - FDA signs off on expanded compassionate use for Avita Med&#39;s skin cell harvesting device; shares up 12% https://seekingalpha.com/news/3330248-fda-signs-off-on-expanded-compassionate-use-for-avita-meds-skin-cell-harvesting-device-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3330248-fda-signs-off-on-expanded-compassionate-use-for-avita-meds-skin-cell-harvesting-device-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330247\" data-ts=\"1518460559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMTL\" target=\"_blank\">CMTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330247-comtech-telecommunications-announces-contract-renewal-worth-4_6m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comtech Telecommunications announces contract renewal worth $4.6M</a></h4><ul>     <li>Comtech Telecommunication's (<a href='https://seekingalpha.com/symbol/CMTL' title='Comtech Telecommunications Corp.'>CMTL</a> <font color='green'>+0.7%</font>) commercial solution segment has received a contract renewal worth ~$4.6M from one of the largest wireless carriers in the United States renewing the licensing for Comtech&rsquo;s next-generation tracking and geo-fencing solution.</li>     <li>&ldquo;We are pleased that our customer has chosen us to continue to provide them with our advanced location-based solutions across a number of connected markets,&rdquo; said Fred Kornberg, President and Chief Executive Officer of Comtech Telecommunications Corp. &ldquo;We are looking forward to supporting this customer with other solutions and services.&rdquo;</li><li><a href=\"https://seekingalpha.com/pr/17071948-comtech-telecommunications-corp-announces-contract-renewal-worth-4_6-million-u-s-wireless\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3330247\" data-linked=\"Comtech Telecommunications announces contract renewal worth $4.6M\" data-tweet=\"$CMTL - Comtech Telecommunications announces contract renewal worth $4.6M https://seekingalpha.com/news/3330247-comtech-telecommunications-announces-contract-renewal-worth-4_6m?source=tweet\" data-url=\"https://seekingalpha.com/news/3330247-comtech-telecommunications-announces-contract-renewal-worth-4_6m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330241\" data-ts=\"1518459257\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRV\" target=\"_blank\">CTRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330241-contravir-to-use-abbreviated-regulatory-path-for-hbv-candidate-txl-shares-up-26\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ContraVir to use abbreviated regulatory path for HBV candidate TXL; shares up 26%</a></h4><ul><li>The FDA has <a href=\"https://seekingalpha.com/pr/17071377-contravir-pharmaceuticals-reaches-agreement-fda-nda-package-txl-leveraging-505-b-2-regulatory\" target=\"_blank\">signed off</a> on allowing ContraVir Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a> <font color='green'>+26%</font>) to use the abbreviated 505(b)(2) regulatory pathway for HBV candidate TXL, allowing it to use data generated by others.</li><li>The company says the shortened regulatory path will trim 12 - 18 months off its nonclinical development program.</li><li>The company and the FDA&nbsp; have also agreed on the principal elements of a Phase 3 study in treatment-naive chronic HBV patients as well as the number of patients in the safety database.</li><li>TXL (tenofovir exalidex) is a highly potent prodrug of tenofovir.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330241\" data-linked=\"ContraVir to use abbreviated regulatory path for HBV candidate TXL; shares up 26%\" data-tweet=\"$CTRV $HEPA - ContraVir to use abbreviated regulatory path for HBV candidate TXL; shares up 26% https://seekingalpha.com/news/3330241-contravir-to-use-abbreviated-regulatory-path-for-hbv-candidate-txl-shares-up-26?source=tweet\" data-url=\"https://seekingalpha.com/news/3330241-contravir-to-use-abbreviated-regulatory-path-for-hbv-candidate-txl-shares-up-26\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330242\" data-ts=\"1518459224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330242-seattle-times-amazon-cutting-several-hundred-hq-jobs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seattle Times: Amazon cutting several hundred HQ jobs</a></h4><ul><li>           Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) will cut several hundred jobs in Seattle, according to <a href=\"https://www.seattletimes.com/business/amazon/amazon-laying-off-corporate-employees-in-rare-cutback/\" target=\"_blank\">The Seattle Times</a> sources. </li><li>           &rdquo;Hundreds&rdquo; more will be laid off elsewhere in the tech giant&rsquo;s global operations including at self-publishing unit Createspace and footwear seller Zappos.  </li><li> The layoffs primarily focus on the consumer retail business. Insiders say rapid growth left some units over budget and overstaffed. </li><li> Amazon broadly addresses the cuts in a statement: &ldquo;As part of our annual planning process, we are making head count adjustments across the company &ndash; small reductions in a couple of places and aggressive hiring in many others.&rdquo;&nbsp; </li><li>Amazon shares are&nbsp;<font color='green'>up 2.7%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3330188-information-amazon-plans-develop-ai-chips\" target=\"_blank\">The Information: Amazon plans to develop AI chips</a> (Feb. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330242\" data-linked=\"Seattle Times: Amazon cutting several hundred HQ jobs\" data-tweet=\"$AMZN - Seattle Times: Amazon cutting several hundred HQ jobs https://seekingalpha.com/news/3330242-seattle-times-amazon-cutting-several-hundred-hq-jobs?source=tweet\" data-url=\"https://seekingalpha.com/news/3330242-seattle-times-amazon-cutting-several-hundred-hq-jobs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330240\" data-ts=\"1518459068\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ULTA\" target=\"_blank\">ULTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330240-oppenheimer-defends-ulta-beauty\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oppenheimer defends Ulta Beauty</a></h4><ul> <li>Oppenheimer analyst Rupesh Parikh advises that any selling violations by Ulta Beauty (<a href='https://seekingalpha.com/symbol/ULTA' title='Ulta Beauty, Inc.'>ULTA</a> <font color='red'>-4.6%</font>) are likely limited in scope and shouldn't be considered as a \"numbers-changing development\" as far as estimates.</li><li>Ulta Beauty is <font color='red'>down 4.51%</font> on the day. Shares traded as low as $204.75 earlier.</li><li>Sources: MarketWatch, Bloomberg</li>  <li>Previously: <a href=\"https://seekingalpha.com/news/3330185-ulta-beauty-falls-wwd-report\" target=\"_blank\">Ulta Beauty falls after WWD report</a> (Feb. 12)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3330240\" data-linked=\"Oppenheimer defends Ulta Beauty\" data-tweet=\"$ULTA - Oppenheimer defends Ulta Beauty https://seekingalpha.com/news/3330240-oppenheimer-defends-ulta-beauty?source=tweet\" data-url=\"https://seekingalpha.com/news/3330240-oppenheimer-defends-ulta-beauty\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330239\" data-ts=\"1518459052\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BP\" target=\"_blank\">BP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330239-bps-dudley-says-expects-to-invest-1b-in-egypt-this-year\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BP&#39;s Dudley says expects to invest $1B in Egypt this year</a></h4><ul>     <li>BP (<a href='https://seekingalpha.com/symbol/BP' title='BP p.l.c.'>BP</a> <font color='green'>+1.9%</font>) is looking to <a href=\"https://www.nasdaq.com/article/bp-ceo-says-to-invest-1-bln-in-egypt-this-year-not-owed-money-20180212-00775\" target=\"_blank\">invest more than $1B in Egypt this year</a>, making the country once again a top destination for investment, CEO Bob Dudley tells an industry event in the country.</li>     <li>The CEO also says the company is no longer owed any money by the Egyptian government, after being owed $2.4B at the end of June 2017.</li>     <li>Dudley also says he is \"<a href=\"https://www.cnbc.com/2018/02/12/bp-ceo-bob-dudley-very-comfortable-with-oil-prices.html\" target=\"_blank\">very comfortable</a>\" with oil prices at current levels, believing \"we're in a range where the shales will be a shock absorber on the upside and the downside.\"</li>     <li><a href=\"https://seekingalpha.com/news/3330130-bp-begins-production-egypts-atoll-gas-field-ahead-schedule\" target=\"_blank\">Earlier</a>: BP begins production at Egypt's Atoll gas field ahead of schedule (Feb. 12)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330239\" data-linked=\"BP&#39;s Dudley says expects to invest $1B in Egypt this year\" data-tweet=\"$BP - BP&#39;s Dudley says expects to invest $1B in Egypt this year https://seekingalpha.com/news/3330239-bps-dudley-says-expects-to-invest-1b-in-egypt-this-year?source=tweet\" data-url=\"https://seekingalpha.com/news/3330239-bps-dudley-says-expects-to-invest-1b-in-egypt-this-year\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330237\" data-ts=\"1518458475\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330237-averages-up-1-in-afternoon-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Averages up more than 1% in afternoon action</a></h4><ul><li>The S&amp;P 500 and Nasdaq 100 are each&nbsp;<font color='green'>higher by 1.5%</font>, and the Dow&nbsp;<font color='green'>by 1.75%</font>, continuing a major rally from Friday afternoon.</li><li>The S&amp;P 500 is now&nbsp;<font color='green'>up about 5%</font>&nbsp;since then.</li><li><strong>Update at 3:30 ET:</strong> Thirty minutes before the close, the Dow is&nbsp;<font color='green'>up 2.2%</font>, the Nasdaq&nbsp;<font color='green'>2.1%</font>, and S&amp;P 500&nbsp;<font color='green'>1.9%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3330237\" data-linked=\"Averages up more than 1% in afternoon action\" data-tweet=\"Averages up more than 1% in afternoon action https://seekingalpha.com/news/3330237-averages-up-1-in-afternoon-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3330237-averages-up-1-in-afternoon-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330238\" data-ts=\"1518458420\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NHLD\" target=\"_blank\">NHLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330238-financials-top-5-gainers-losers-of-1-00-pm-02-12-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM (02/12/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NHLD' title='National Holdings Corp.'>NHLD</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a> <font color='green'>+12%</font>.<a href='https://seekingalpha.com/symbol/PMTS' title='CPI Card Group'>PMTS</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/OZM' title='Och-Ziff Capital Management Group LLC'>OZM</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VIRT' title='Virtu Financial, Inc.'>VIRT</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330238\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM (02/12/2018)\" data-tweet=\"$NHLD $NHLD $GROW - Financials - Top 5 Gainers / Losers as of 1:00 PM (02/12/2018) https://seekingalpha.com/news/3330238-financials-top-5-gainers-losers-of-1-00-pm-02-12-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3330238-financials-top-5-gainers-losers-of-1-00-pm-02-12-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330233\" data-ts=\"1518458118\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RARX\" target=\"_blank\">RARX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330233-alexion-up-5-on-difficulty-in-certain-pnh-patients-switching-from-soliris-to-ra-pharmas\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alexion up 5% on difficulty in certain PNH patients switching from Soliris to Ra Pharma&#39;s RA101495</a></h4><ul><li>A <a href=\"https://seekingalpha.com/pr/17071418-ra-pharmaceuticals-announces-completion-dosing-phase-2-program-ra101495-sc-paroxysmal\" target=\"_blank\">Phase 2 clinical trial</a> assessing Ra Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/RARX' title='Ra Pharmaceuticals'>RARX</a> <font color='green'>+2.4%</font>) subcutaneously administered RA101495 in patients with paroxysmal nocturnal hemoglobinuria &#40;PNH&#41; showed a positive effect in patients who were naive to Alexion Therapeutics' (<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a> <font color='green'>+5.3%</font>) Soliris (eculizumab). The data weren't so good for patients on Soliris therapy, however.</li><li>In 10 PNH patients naive to Soliris, treatment with RA101495 met the primary endpoint of a sustained reduction in lactate dehydrogenase &#40;LDH&#41; levels from baseline to the mean of weeks 6 - 12 (p=0.002) with near-complete suppression of complement activity. Half (n=3/6) of the transfusion-dependent subjects prior to enrollment remained transfusion-free during the study period.</li><li>In patients on Soliris who switched to RA101495, five transfusion-independent patients maintained stable LDH levels with one withdrawal due to breakthrough hemolysis (return of PNH symptoms) who returned to Soliris without complications.</li><li>In transfusion-dependent Soliris switch patients, breakthrough hemolysis occurred in 64% of subjects (n=7/11), all of whom reverted back to Soliris without complications. Persistent transfusion-dependence occurs in up to 20% of PNH sufferers.</li><li>The company is undeterred. It plans to launch Phase 3 studies in both Soliris-naive and Soliris-experienced transfusion-independent patients.</li><li>The value proposition of RA101495 SC, a complement component 5 inhibitor, is self-administered subcutaneous injection. Soliris is a monoclonal antibody administered via IV infusion over a period of 35 minutes.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316060-ra-pharma-announces-mid-stage-data-pnh-candidate-ra101495-certain-patients-fail-tolerate\" target=\"_blank\">Ra Pharma announces mid-stage data on PNH candidate RA101495, certain patients fail to tolerate switch from Soliris; shares down 31%</a> (Dec. 4, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330233\" data-linked=\"Alexion up 5% on difficulty in certain PNH patients switching from Soliris to Ra Pharma&#39;s RA101495\" data-tweet=\"$RARX $RARX $ALXN - Alexion up 5% on difficulty in certain PNH patients switching from Soliris to Ra Pharma&#39;s RA101495 https://seekingalpha.com/news/3330233-alexion-up-5-on-difficulty-in-certain-pnh-patients-switching-from-soliris-to-ra-pharmas?source=tweet\" data-url=\"https://seekingalpha.com/news/3330233-alexion-up-5-on-difficulty-in-certain-pnh-patients-switching-from-soliris-to-ra-pharmas\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330232\" data-ts=\"1518457730\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DARE\" target=\"_blank\">DARE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330232-midday-gainers-losers-2-12-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (2/12/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DARE' title='Dare Bioscience, Inc.'>DARE</a> <font color='green'>+49%</font>. <a href='https://seekingalpha.com/symbol/AMBR' title='Amber Road, Inc.'>AMBR</a> <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a> <font color='green'>+34%</font>. <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='green'>+32%</font>. <a href='https://seekingalpha.com/symbol/CSRA' title='CSRA Inc.'>CSRA</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/AQMS' title='Aqua Metals'>AQMS</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/IFRX' title='InflaRx N.V.'>IFRX</a> <font color='green'>+21%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/QUMU' title='Qumu Corporation'>QUMU</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/AVGR' title='Avinger'>AVGR</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/OHGI' title='One Horizon Group, Inc.'>OHGI</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/SPNS' title='Sapiens International Corporation N.V.'>SPNS</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/TCON' title='Tracon Pharmaceuticals'>TCON</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CSPI' title='CSP Inc.'>CSPI</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/RVLT' title='Revolution Lighting Technologies, Inc.'>RVLT</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/SMI' title='Semiconductor Manufacturing International Corporation'>SMI</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/STMP' title='Stamps.com Inc.'>STMP</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330232\" data-linked=\"Midday Gainers / Losers (2/12/2018)\" data-tweet=\"$DARE $DARE $AMBR - Midday Gainers / Losers (2/12/2018) https://seekingalpha.com/news/3330232-midday-gainers-losers-2-12-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3330232-midday-gainers-losers-2-12-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330231\" data-ts=\"1518457295\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LNG\" target=\"_blank\">LNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330231-cheniere-says-lng-output-not-affected-shutdown-of-leaky-storage-tanks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cheniere says LNG output not affected by shutdown of leaky storage tanks</a></h4><ul>     <li>Cheniere Energy (<a href='https://seekingalpha.com/symbol/LNG' title='Cheniere Energy, Inc'>LNG</a> <font color='green'>+1.6%</font>) says production of liquefied natural gas from its Sabine Pass export plant in Louisiana <a href=\"https://www.reuters.com/article/cheniere-energy-lng-outages/cheniere-lng-production-unaffected-by-shutdown-of-leaky-storage-tanks-idUSL8N1Q255E\" target=\"_blank\">will not be affected</a> by an order to shut two cracked storage tanks that leaked the fuel.</li>     <li>The U.S. Department of Pipeline and Hazardous Materials Safety Administration last week ordered the company to shut two LNG storage tanks after <a href=\"https://www.eenews.net/stories/1060073537\" target=\"_blank\">discovering multiple leaks</a>, raising the possibility that similar leaks may have occurred in multiple tanks.</li><li>Cheniere \"cannot validate the exact source or amount\" of leaked LNG and  \"cannot identify the circumstances that allowed the LNG to escape  containment in the first place,\" PHMSA said in its corrective action order that called on the company to  complete a thorough assessment of the problems.</li>     <li>PHMSA allowed Cheniere to continue importing and exporting gas and use three other LNG storage tanks at the site.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330231\" data-linked=\"Cheniere says LNG output not affected by shutdown of leaky storage tanks\" data-tweet=\"$LNG - Cheniere says LNG output not affected by shutdown of leaky storage tanks https://seekingalpha.com/news/3330231-cheniere-says-lng-output-not-affected-shutdown-of-leaky-storage-tanks?source=tweet\" data-url=\"https://seekingalpha.com/news/3330231-cheniere-says-lng-output-not-affected-shutdown-of-leaky-storage-tanks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330228\" data-ts=\"1518455796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TMST\" target=\"_blank\">TMST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330228-timkensteel-tops-nyse-gainers-after-keybanc-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TimkenSteel tops NYSE gainers after KeyBanc upgrade</a></h4><ul>     <li>TimkenSteel (<a href='https://seekingalpha.com/symbol/TMST' title='TimkenSteel Corp.'>TMST</a> <font color='green'>+14.7%</font>) is today's top performer on the NYSE after KeyBanc <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/02/11175999/keybanc-projects-17-upside-in-timkensteel-corp-shares\" target=\"_blank\">upgraded</a> shares to Overweight from Sector Weight with a $17 price target following a recent sharp pullback.</li>     <li>An attractive valuation after the recent sell-off, modest incremental improvement in industry spot pricing and the emergence of a stronger free cash flow estimate drove the upgrade, the firm says.</li>     <li>KeyBanc's 2018 HRC pricing estimate has climbed to $670/ton from $655 while maintaining its CRC view at $825/ton, lowering the HRC-to-CRC spread to $155/ton vs. $190 in 2017.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330228\" data-linked=\"TimkenSteel tops NYSE gainers after KeyBanc upgrade\" data-tweet=\"$TMST - TimkenSteel tops NYSE gainers after KeyBanc upgrade https://seekingalpha.com/news/3330228-timkensteel-tops-nyse-gainers-after-keybanc-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3330228-timkensteel-tops-nyse-gainers-after-keybanc-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330226\" data-ts=\"1518455055\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBY\" target=\"_blank\">NBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330226-novabay-completes-private-6m-capital-raise-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NovaBay completes private $6M capital raise; shares up 1%</a></h4><ul><li>NovaBay Pharmaceuticals (<a href='https://seekingalpha.com/symbol/NBY' title='NovaBay Pharmaceuticals, Inc.'>NBY</a> <font color='green'>+1.1%</font>) <a href=\"https://seekingalpha.com/pr/17071408-novabay-pharmaceuticals-completes-6_0-million-private-placement\" target=\"_blank\">completes </a>the private sale of 1.7M shares of common stock to Chinese institutional investor OP Financial Investments Limited. Gross proceeds were $5,984,000 ($3.52/share).</li></ul><div class=\"tiny-share-widget\" data-id=\"3330226\" data-linked=\"NovaBay completes private $6M capital raise; shares up 1%\" data-tweet=\"$NBY - NovaBay completes private $6M capital raise; shares up 1% https://seekingalpha.com/news/3330226-novabay-completes-private-6m-capital-raise-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3330226-novabay-completes-private-6m-capital-raise-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330225\" data-ts=\"1518454956\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOX\" target=\"_blank\">FOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330225-rosenblatt-talk-of-counter-bid-from-comcast-lends-fox-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rosenblatt: Talk of counter-bid from Comcast lends Fox upside</a></h4><ul>   <li>Talk of Comcast (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='red'>-0.1%</font>) potentially getting back into the race for Fox media assets has Rosenblatt's Alan Gould <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/02/11176458/rosenblatt-comcast-challenge-for-fox-assets-could-reduc\" target=\"_blank\">reiterating his Buy</a> on Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='green'>+3%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='green'>+2.7%</font>).</li>    <li>Comcast is said to be valuing the same media assets that Disney is set to buy, including international platforms and Hulu, though Fox reportedly wanted Disney shares rather than a higher price from Comcast.</li>    <li>&ldquo;We don&rsquo;t know if Comcast will indeed bid, but at a minimum, we would think the prospects of a competitive bid should reduce the arbitrage discount investors are putting on Fox,&rdquo; Gould writes. He sees a possible $46/share bid from Comcast likely prompting a counter-bid from Disney, who's at $40 now.</li>    <li>He has a $43 price target on Fox.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3330045-comcast-mulling-new-bid-fox-assets\" target=\"_blank\">Comcast mulling new bid for Fox assets</a> (Feb. 12 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330225\" data-linked=\"Rosenblatt: Talk of counter-bid from Comcast lends Fox upside\" data-tweet=\"$FOX $FOX $FOXA - Rosenblatt: Talk of counter-bid from Comcast lends Fox upside https://seekingalpha.com/news/3330225-rosenblatt-talk-of-counter-bid-from-comcast-lends-fox-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3330225-rosenblatt-talk-of-counter-bid-from-comcast-lends-fox-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330224\" data-ts=\"1518454946\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICON\" target=\"_blank\">ICON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330224-consumer-top-gainers-losers-of-12-00-pm-2-12-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm (2/12/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/FORD' title='Forward Industries, Inc.'>FORD</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/OBCI' title='Ocean Bio-Chem, Inc.'>OBCI</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/WMS' title='Advanced Drainage Systems'>WMS</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/COLM' title='Columbia Sportswear Company'>COLM</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/MCFT' title='MasterCraft Boat Holdings, Inc.'>MCFT</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330224\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm (2/12/2018)\" data-tweet=\"$ICON $ICON $FORD - Consumer - Top Gainers / Losers as of 12:00 pm (2/12/2018) https://seekingalpha.com/news/3330224-consumer-top-gainers-losers-of-12-00-pm-2-12-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3330224-consumer-top-gainers-losers-of-12-00-pm-2-12-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330219\" data-ts=\"1518454346\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWLO\" target=\"_blank\">TWLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330219-twilioplus-2_6-after-appointing-chief-partners-officer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twilio +2.6% after appointing Chief Partners Officer</a></h4><ul><li>        Twilio (NYSE:<a href='https://seekingalpha.com/symbol/TWLO' title='Twilio'>TWLO</a>) <a href=\"https://seekingalpha.com/pr/17071847-twilio-welcomes-ron-huddleston-chief-partners-officer\" target=\"_blank\">announces</a> that Ron Huddleston will join the company as Chief Partners Officer.</li><li>               Huddleston&rsquo;s work history includes Microsoft and Salesforce.&nbsp;</li><li>               Twilio shares are&nbsp;<font color='green'>up 2.6%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3330219\" data-linked=\"Twilio +2.6% after appointing Chief Partners Officer\" data-tweet=\"$TWLO - Twilio +2.6% after appointing Chief Partners Officer https://seekingalpha.com/news/3330219-twilioplus-2_6-after-appointing-chief-partners-officer?source=tweet\" data-url=\"https://seekingalpha.com/news/3330219-twilioplus-2_6-after-appointing-chief-partners-officer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330216\" data-ts=\"1518453844\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GD\" target=\"_blank\">GD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330216-government-service-stocks-higher-after-general-dynamics-deal-for-csra\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Government service stocks higher after General Dynamic&#39;s deal for CSRA</a></h4><ul>     <li>General  Dynamics' (<a href='https://seekingalpha.com/symbol/GD' title='General Dynamics Corporation'>GD</a> <font color='red'>-0.2%</font>) <a href=\"https://seekingalpha.com/news/3330106-general-dynamics-acquire-csra-9_6b\" target=\"_blank\">$9.6B deal</a> for government IT services provider CSRA is pushing several other  government service stocks higher, including Leidos (<a href='https://seekingalpha.com/symbol/LDOS' title='Leidos Holdings, Inc.'>LDOS</a> <font color='green'>+2%</font>), CACI International (<a href='https://seekingalpha.com/symbol/CACI' title='CACI International Inc'>CACI</a> <font color='green'>+3.5%</font>),  SAIC (<a href='https://seekingalpha.com/symbol/SAIC' title='Science Applications International Corporation'>SAIC</a> <font color='green'>+2.2%</font>) and Booz Allen (<a href='https://seekingalpha.com/symbol/BAH' title='Booz Allen Hamilton Holding Corporation'>BAH</a> <font color='green'>+2.4%</font>).</li>     <li>&ldquo;An increasing [U.S. defense] budget going forward gives us cause for optimism that the services market is going to come back to pre-2011 characteristics,&rdquo; <a href=\"https://www.reuters.com/article/us-csra-m-a-general-dynamics/general-dynamics-to-buy-federal-services-provider-for-6-8-billion-idUSKBN1FW14U\" target=\"_blank\">says</a> Daniel Johnson, head of GD's information systems and technology unit.</li>     <li>RBC Capital analyst Matthew McConnell says the deal price looks \"reasonable,\" and the likelihood is low that another top defense contractor would top GD's offer since most are de-emphasizing their IT services businesses.</li>     <li>The agreement puts GD's chronically underlevered balance sheet to work in a niche it knows well and without margin dilution given CSRA's premium  profitability in the IT services sector, McConnell says.</li>     <li>Source :&nbsp;Bloomberg First Word</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330216\" data-linked=\"Government service stocks higher after General Dynamic&#39;s deal for CSRA\" data-tweet=\"$GD $GD $LDOS - Government service stocks higher after General Dynamic&#39;s deal for CSRA https://seekingalpha.com/news/3330216-government-service-stocks-higher-after-general-dynamics-deal-for-csra?source=tweet\" data-url=\"https://seekingalpha.com/news/3330216-government-service-stocks-higher-after-general-dynamics-deal-for-csra\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330215\" data-ts=\"1518453481\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAP\" target=\"_blank\">SAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330215-sap-ceo-future-m-wont-be-large-enough-to-move-needle\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SAP CEO: Future M&amp;A won&#39;t be large &quot;enough to move the needle&quot;</a></h4><ul><li>        SAP&rsquo;s (NYSE:<a href='https://seekingalpha.com/symbol/SAP' title='SAP AG'>SAP</a>) acquisition plans could involve some &ldquo;tuck-ins&rdquo; but &ldquo;small in nature, not enough to move the needle,&rdquo; according to CEO Bill McDermott in comments to <a href=\"https://www.cnbc.com/2018/02/12/sap-will-do-small-tuck-in-acquisitions-not-mega-deals-ceo-bill-mcdermott.html\" target=\"_blank\">CNBC</a>.&nbsp; &nbsp;</li><li>        Last month, SAP announced acquiring Callidus Software for $2.4B.</li><li>                  McDermott notes the Callidus deal was the company&rsquo;s largest acquisition in over three years but counts it as a &ldquo;tuck-in based on its size.&rdquo;    </li><li>               The CEO also says that heavy data center investments are &ldquo;largely behind us&rdquo; and watchers should &ldquo;expect margins to bend now, the revenue to continue to grow strong in the cloud.&rdquo;&nbsp;</li><li>               SAP shares are&nbsp;<font color='green'>up 0.5%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3326271-sap-buys-callidus-software-2_4b\" target=\"_blank\">SAP buys Callidus Software for $2.4B</a> (Jan. 30)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330215\" data-linked=\"SAP CEO: Future M&amp;A won&#39;t be large &quot;enough to move the needle&quot;\" data-tweet=\"$SAP - SAP CEO: Future M&amp;A won&#39;t be large &quot;enough to move the needle&quot; https://seekingalpha.com/news/3330215-sap-ceo-future-m-wont-be-large-enough-to-move-needle?source=tweet\" data-url=\"https://seekingalpha.com/news/3330215-sap-ceo-future-m-wont-be-large-enough-to-move-needle\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330214\" data-ts=\"1518453193\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVRA\" target=\"_blank\">SVRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330214-savara-expands-enrollment-in-late-stage-pap-study-of-molgradex-top-line-data-expected-in-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Savara expands enrollment in late-stage PAP study of Molgradex, top-line data expected in Q2 2019; shares up 3%</a></h4><ul><li>The FDA has <a href=\"https://seekingalpha.com/pr/17071537-savara-announces-ind-approval-expansion-molgradex-phase-3-study-u-s\" target=\"_blank\">signed off </a>on Savara's (<a href='https://seekingalpha.com/symbol/SVRA' title='Savara Inc.'>SVRA</a> <font color='green'>+2.6%</font>) IND for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of <a href=\"https://rarediseases.info.nih.gov/diseases/7499/autoimmune-pulmonary-alveolar-proteinosis\" target=\"_blank\">autoimmune pulmonary alveolar proteinosis</a> &#40;PAP&#41;, a rare lung disorder in which pulmonary surfactant accumulates in the alveoli (tiny air sacs in the lungs) interfering with oxygen/carbon dioxide exchange.</li><li>The IND enables the company to expand enrollment in the Phase 3 IMPALA study to 135 from 90, expected to be completed by Q3. Top-line results should be available by Q2 2019.</li><li>Alveolar cells called macrophages need to be stimulated by GM-CSF in order to effectively clear surfactant. In PAP, GM-CSF is neutralized by antibodies.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330214\" data-linked=\"Savara expands enrollment in late-stage PAP study of Molgradex, top-line data expected in Q2 2019; shares up 3%\" data-tweet=\"$SVRA - Savara expands enrollment in late-stage PAP study of Molgradex, top-line data expected in Q2 2019; shares up 3% https://seekingalpha.com/news/3330214-savara-expands-enrollment-in-late-stage-pap-study-of-molgradex-top-line-data-expected-in-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3330214-savara-expands-enrollment-in-late-stage-pap-study-of-molgradex-top-line-data-expected-in-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330208\" data-ts=\"1518452197\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HUSA\" target=\"_blank\">HUSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330208-houston-american-energy-announces-preliminary-q4-revenues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Houston American Energy announces preliminary Q4 revenues</a></h4><ul>     <li>Houston American Energy (<a href='https://seekingalpha.com/symbol/HUSA' title='Houston American Energy Corp.'>HUSA</a> <font color='green'>+25.5%</font>) expects Q4 revenue of $0.41M (+842% Y/Y).</li><li><a href=\"https://seekingalpha.com/pr/17072015-houston-american-energy-corp-announces-preliminary-fourth-quarter-2017-revenues-updates\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3330208\" data-linked=\"Houston American Energy announces preliminary Q4 revenues\" data-tweet=\"$HUSA - Houston American Energy announces preliminary Q4 revenues https://seekingalpha.com/news/3330208-houston-american-energy-announces-preliminary-q4-revenues?source=tweet\" data-url=\"https://seekingalpha.com/news/3330208-houston-american-energy-announces-preliminary-q4-revenues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330202\" data-ts=\"1518451402\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPNT\" target=\"_blank\">OPNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330202-opiant-on-go-abbreviated-regulatory-path-for-long-acting-intranasal-opioid-overdose-treatment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Opiant on go with abbreviated regulatory path for long-acting intranasal opioid overdose treatment; shares up 2%</a></h4><ul><li>Thinly traded nano cap Opiant Pharmaceuticals (<a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='green'>+2.2%</font>) perks up, albeit on light volume, on the heels of its <a href=\"https://seekingalpha.com/pr/17071602-opiant-pharmaceuticals-announces-development-opnt003-intranasal-nalmefene-treatment-opioid\" target=\"_blank\">regulatory plan</a> for OPNT003, a long-acting intranasal treatment for opioid overdose.</li><li>Based on FDA feedback, the company will pursue a 505(b)(2) development path which allows the inclusion of data generated by others. The company anticipates filing a New Drug Application in 2020.</li><li>The active ingredient in OPNT003 is nalmefene, combined with an absorption enhancer called Intravail, developed by Aegis Therapeutics. Phase 1 data showed a rapid increase in plasma levels with an onset of action faster than an intramuscular injection. It also has a half-life of 6.7 - 7.8 hours, over three times as long as <a href=\"https://www.narcan.com/\" target=\"_blank\">NARCAN </a>(naloxone) (two hours), the only current FDA-approved nasal spray for the emergency treatment of opioid overdose.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330202\" data-linked=\"Opiant on go with abbreviated regulatory path for long-acting intranasal opioid overdose treatment; shares up 2%\" data-tweet=\"$OPNT - Opiant on go with abbreviated regulatory path for long-acting intranasal opioid overdose treatment; shares up 2% https://seekingalpha.com/news/3330202-opiant-on-go-abbreviated-regulatory-path-for-long-acting-intranasal-opioid-overdose-treatment?source=tweet\" data-url=\"https://seekingalpha.com/news/3330202-opiant-on-go-abbreviated-regulatory-path-for-long-acting-intranasal-opioid-overdose-treatment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330182\" data-ts=\"1518451312\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DARE\" target=\"_blank\">DARE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330182-healthcare-top-5-gainers-losers-of-11-00-2-12-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am (2/12/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DARE' title='Dare Bioscience, Inc.'>DARE</a> <font color='green'>+47%</font>. <a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='green'>+17%</font>. APRI <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/IFRX' title='InflaRx N.V.'>IFRX</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/TCON' title='Tracon Pharmaceuticals'>TCON</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/TTNP' title='Titan Pharmaceuticals, Inc.'>TTNP</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/ATRA' title='Atara Biotherapeutics'>ATRA</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330182\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am (2/12/2018)\" data-tweet=\"$DARE $DARE $HTGM - Healthcare - Top 5 Gainers / Losers as of 11:00 am (2/12/2018) https://seekingalpha.com/news/3330182-healthcare-top-5-gainers-losers-of-11-00-2-12-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3330182-healthcare-top-5-gainers-losers-of-11-00-2-12-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330201\" data-ts=\"1518451291\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WWE\" target=\"_blank\">WWE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330201-wweplus-2_7-keybanc-sees-positive-catalysts-in-tv-renewal-wrestlemania\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WWE +2.7% as KeyBanc sees positive catalysts in TV renewal, WrestleMania</a></h4><ul>   <li>World Wrestling Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/WWE' title='World Wrestling Entertainment, Inc.'>WWE</a>) is <font color='green'>up 2.7%</font> after an upgrade to Overweight at KeyBanc, which sees positivity ahead in its TV renewals and a key catalyst in April's WrestleMania event.</li>    <li>TV revenue from major distributors will rise 30% Y/Y in 2020, writes analyst Evan Wingren, with annual escalators coming after that. (h/t Bloomberg)</li>    <li>Meanwhile, coming up this year is a TV announcement expected between May and September that \"will likely be extrapolated for other TV contracts\" and a WrestleMania event that will likely be the determining factor for the company's annual subscriber growth.</li>    <li>Wingren has a price target of $43, implying 20% upside from current pricing.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3330201\" data-linked=\"WWE +2.7% as KeyBanc sees positive catalysts in TV renewal, WrestleMania\" data-tweet=\"$WWE - WWE +2.7% as KeyBanc sees positive catalysts in TV renewal, WrestleMania https://seekingalpha.com/news/3330201-wweplus-2_7-keybanc-sees-positive-catalysts-in-tv-renewal-wrestlemania?source=tweet\" data-url=\"https://seekingalpha.com/news/3330201-wweplus-2_7-keybanc-sees-positive-catalysts-in-tv-renewal-wrestlemania\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330197\" data-ts=\"1518450528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DO\" target=\"_blank\">DO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330197-diamond-offshoreminus-3-after-q4-loss-reduced-revenues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diamond Offshore -3% after Q4 loss, reduced revenues</a></h4><ul>     <li>Diamond Offshore Drilling (<a href='https://seekingalpha.com/symbol/DO' title='Diamond Offshore Drilling Inc.'>DO</a> <font color='red'>-3.8%</font>) is sharply lower despite reporting a smaller than expected <a href=\"https://seekingalpha.com/news/3330057-diamond-offshore-drilling-beats-0_01-beats-revenue\" target=\"_blank\">Q4 loss</a>, as revenues came in 12% lower Y/Y.</li>     <li>DO reported an unadjusted net loss of $31.9M, or a $0.23/share loss, in Q4 vs. a $10.8M net profit, or $0.08/share, in Q3 and a year-ago profit of $116M, or $0.85/share, as it took a $28M impairment charge related to its rigs.</li>     <li>Operational efficiency of the company's fleet was 98.8% in Q4, compared to 94.3% in Q3.</li>     <li>DO says its <em>Ocean Guardian</em> semi-submersible drilling rig won a contract with Chevron in the U.K. starting in May and ending in September, the <em>Ocean Valiant</em> rig was awarded a well-based contract from Maersk in the U.K.; the well-based contract <a href=\"https://seekingalpha.com/article/4145629-diamond-offshore-q4-report-brings-new-contracts\" target=\"_blank\">may prove riskier</a> than the typical dayrate contract since the job may take more time than originally expected.</li>     <li>Tudor Pickering Holt analyst Taylor Zurcher says demand continues to &ldquo;surprise to upside&rdquo; but likely will not be long enough to drive any notable pricing momentum in the near-term, suggesting an <a href=\"https://www.reuters.com/article/us-diamond-offshore-results/diamond-offshore-says-path-to-recovery-starting-to-take-shape-idUSKBN1FW13Y\" target=\"_blank\">offshore recovery could take longer than expected</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330197\" data-linked=\"Diamond Offshore -3% after Q4 loss, reduced revenues\" data-tweet=\"$DO - Diamond Offshore -3% after Q4 loss, reduced revenues https://seekingalpha.com/news/3330197-diamond-offshoreminus-3-after-q4-loss-reduced-revenues?source=tweet\" data-url=\"https://seekingalpha.com/news/3330197-diamond-offshoreminus-3-after-q4-loss-reduced-revenues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330195\" data-ts=\"1518449927\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICON\" target=\"_blank\">ICON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330195-iconix-brand-flies-after-posting-business-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iconix Brand flies after posting business update</a></h4><ul> <li>Iconix Brand Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a>) rips a <font color='green'>31% gain</font> after issuing 2018 revenue guidance for a range of $190M to $220M.</li> <li>The company also updated today that it landed a multi-year license deal with Target for the Umbro soccer brand and lost a Royal Velvet license arrangement with J.C. Penney.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3330195\" data-linked=\"Iconix Brand flies after posting business update\" data-tweet=\"$ICON - Iconix Brand flies after posting business update https://seekingalpha.com/news/3330195-iconix-brand-flies-after-posting-business-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3330195-iconix-brand-flies-after-posting-business-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330190\" data-ts=\"1518448852\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SDRL\" target=\"_blank\">SDRL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330190-seadrill-nearing-comprehensive-restructuring-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seadrill nearing comprehensive restructuring deal</a></h4><ul>     <li>Bankrupt Seadrill (<a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited &#40;New&#41;'>SDRL</a> <font color='green'>+8.8%</font>) is working towards a comprehensive deal with all its creditors that <a href=\"https://www.reuters.com/article/uk-seadrill-bankruptcy/seadrill-nears-comprehensive-restructuring-deal-court-filing-idUSKBN1FW0FX\" target=\"_blank\">could be concluded this week</a>, according to a court filing late Friday.</li>     <li>Discussions were trying to incorporate proposals made in two alternative plans by creditors Barclays Capital and an ad hoc group of bondholders, SDRL says in the filing.</li>     <li>SDRL has been working with creditors on a restructuring plan to bring in $1B-plus in fresh funding and allow it to maintain its fleet of rigs; unsecured bondholders would get a ~15% stake in the company but existing shareholders would be wiped out.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3330190\" data-linked=\"Seadrill nearing comprehensive restructuring deal\" data-tweet=\"$SDRL - Seadrill nearing comprehensive restructuring deal https://seekingalpha.com/news/3330190-seadrill-nearing-comprehensive-restructuring-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3330190-seadrill-nearing-comprehensive-restructuring-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330189\" data-ts=\"1518448803\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPNS\" target=\"_blank\">SPNS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330189-sapiens-announces-preliminary-2017-results-fy18-financial-guidance-shares-tank-16\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sapiens announces preliminary 2017 results &amp; FY18 financial guidance; shares tank 16%</a></h4><ul>     <li>Sapiens (<a href='https://seekingalpha.com/symbol/SPNS' title='Sapiens International Corporation N.V.'>SPNS</a> <font color='red'>-16.1%</font>) expects FY17 Non-GAAP revenue in the range of $271M - $273M vs. a consensus of $273.63M.</li>     <li>Non-GAAP operating margin between 8.3% - 8.6%.</li>     <li><strong>FY2018 Guidance</strong>: Non-GAAP revenue in the range of $280M - $285M vs a consensus of $309.72M.</li>     <li>Non-GAAP operating margin of 12% - 13%.</li>     <li>CEO Roni Al Dor: \"Our full-year 2018 revenue outlook reflects Sapiens' deliberate move away from non-core business, the extension of the roll-out of a large, multi-year contract over a longer period of time, the anticipated reduction in our off-shore local market activities in an effort to support our main focus markets, and the near-term impact of product overlap from the Adaptik acquisition\"</li><li><a href=\"https://seekingalpha.com/pr/17071416-sapiens-announces-preliminary-2017-results-full-year-2018-financial-guidance\" target=\"_blank\">Press Release</a></li>      </ul><div class=\"tiny-share-widget\" data-id=\"3330189\" data-linked=\"Sapiens announces preliminary 2017 results &amp; FY18 financial guidance; shares tank 16%\" data-tweet=\"$SPNS - Sapiens announces preliminary 2017 results &amp; FY18 financial guidance; shares tank 16% https://seekingalpha.com/news/3330189-sapiens-announces-preliminary-2017-results-fy18-financial-guidance-shares-tank-16?source=tweet\" data-url=\"https://seekingalpha.com/news/3330189-sapiens-announces-preliminary-2017-results-fy18-financial-guidance-shares-tank-16\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330188\" data-ts=\"1518448781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330188-information-amazon-plans-to-develop-ai-chips\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Information: Amazon plans to develop AI chips</a></h4><ul><li>        Amazon (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='green'>+0.9%</font>) plans to become an AI chipmaker, according to <a href=\"https://www.theinformation.com/articles/amazon-is-becoming-an-ai-chip-maker-speeding-alexa-responses\" target=\"_blank\">The Information</a> sources.</li><li>               The chips would let Alexa devices respond faster to commands and are in development using tech brought in with the $350M acquisition of Israeli chipmaker Annapurna Labs three years ago.&nbsp;</li><li>               Last December&rsquo;s Blink acquisition brought more chip-making tech to Amazon. The startup was founded as Immedia Semiconductor and built chips for low-power video compression.&nbsp;</li><li>               Amazon Web Services might be working on an AI chip for data centers. &nbsp;&nbsp;</li><li>Amazon shares are&nbsp;<font color='green'>up 0.9%</font>.&nbsp; &nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3330053-amazon-paid-90m-blink-technology\" target=\"_blank\">Amazon paid $90M for Blink technology</a> (Feb. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330188\" data-linked=\"The Information: Amazon plans to develop AI chips\" data-tweet=\"$AMZN - The Information: Amazon plans to develop AI chips https://seekingalpha.com/news/3330188-information-amazon-plans-to-develop-ai-chips?source=tweet\" data-url=\"https://seekingalpha.com/news/3330188-information-amazon-plans-to-develop-ai-chips\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330186\" data-ts=\"1518448531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKBA\" target=\"_blank\">AKBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330186-akebia-and-otsuka-tweak-design-of-late-stage-vadadustat-studies-marketing-approval-in-japan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akebia and Otsuka tweak design of late-stage vadadustat studies, marketing approval in Japan expected in 2020; shares down 2%</a></h4><ul><li>In an <a href=\"https://seekingalpha.com/pr/17071422-akebia-therapeutics-provides-update-vadadustat-development-program\" target=\"_blank\">update </a>to investors, Akebia Therapeutics (<a href='https://seekingalpha.com/symbol/AKBA' title='Akebia Therapeutics, Inc.'>AKBA</a> <font color='red'>-1.6%</font>) announces that it and commercialization partner Otsuka have changed the designs of two Japan-based Phase 3 studies, FO2RWARD and TRILO2GY, evaluating vadadustat in patients with anemia associated with dialysis-dependent chronic kidney disease &#40;DD-CKD&#41;.</li><li>FO2RWARD will now include a broader dialysis population and larger sample size with once-daily and 3x/week dosing. It is designed to inform ESA (erythropoietin stimulating agent)-switching protocols. The study will be initiated next quarter with top-line data expected by year-end/early 2019.</li><li>TRILO2GY will also include a larger sample size and once-daily and 3x/week dosing. It is designed to inform switching from Amgen's Epogen (epoetin alfa) and Aranesp (darbepoetin alfa) and Vifor Pharma's <a href=\"https://www.fda.gov/downloads/Drugs/DrugSafety/ucm088644.pdf\" target=\"_blank\">Mircera </a>(methoxy PEG-epoetin beta). The study will launch by year-end/early 2019 with top-line results expected in early 2020.</li><li>Akebia's two U.S. Phase 3s, INNO2VATE and PRO2TECT, should hit their enrollment targets by year-end. Top-line data are expected in 2019 with market launch to follow on 2020 assuming positive results and the accrual of the required number of major adverse cardiac events &#40;MACE&#41;.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3321205-akebias-vadadustat-shows-positive-results-japan-based-anemia-study\" target=\"_blank\">Akebia's vadadustat shows positive results in Japan-based anemia study</a> (Jan. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330186\" data-linked=\"Akebia and Otsuka tweak design of late-stage vadadustat studies, marketing approval in Japan expected in 2020; shares down 2%\" data-tweet=\"$AKBA - Akebia and Otsuka tweak design of late-stage vadadustat studies, marketing approval in Japan expected in 2020; shares down 2% https://seekingalpha.com/news/3330186-akebia-and-otsuka-tweak-design-of-late-stage-vadadustat-studies-marketing-approval-in-japan?source=tweet\" data-url=\"https://seekingalpha.com/news/3330186-akebia-and-otsuka-tweak-design-of-late-stage-vadadustat-studies-marketing-approval-in-japan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330185\" data-ts=\"1518448242\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ULTA\" target=\"_blank\">ULTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330185-ulta-beauty-falls-after-wwd-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ulta Beauty falls after WWD report</a></h4><ul> <li>Shares of Ulta Beauty (<a href='https://seekingalpha.com/symbol/ULTA' title='Ulta Beauty, Inc.'>ULTA</a> <font color='red'>-4.5%</font>) are lower in morning trading after <em>Women's Wear Daily</em> <a href=\"http://wwd.com/business-news/legal/ulta-sued-over-allegedly-reselling-used-cosmetics-1202548681/\" target=\"_blank\">details</a> more accusations against the retailer on selling used and returned items as new.</li> <li>Many of the anecdotal reports circulating around on Ulta are said to be from ex-employees.</li> <li>A lawsuit related to the matter has been filed against the company in Illinois.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3330185\" data-linked=\"Ulta Beauty falls after WWD report\" data-tweet=\"$ULTA - Ulta Beauty falls after WWD report https://seekingalpha.com/news/3330185-ulta-beauty-falls-after-wwd-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3330185-ulta-beauty-falls-after-wwd-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330175\" data-ts=\"1518446624\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WRD\" target=\"_blank\">WRD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330175-wildhorse-resource-to-sell-north-louisiana-assets-for-217m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WildHorse Resource to sell north Louisiana assets for $217M</a></h4><ul>     <li>WildHorse Resource Development (<a href='https://seekingalpha.com/symbol/WRD' title='WildHorse Resource Development'>WRD</a> <font color='green'>+6.3%</font>) opens higher after <a href=\"https://seekingalpha.com/pr/17071353-wildhorse-resource-development-corporation-announces-divestment-north-louisiana-assets\" target=\"_blank\">agreeing to sell</a> its north Louisiana assets to an unnamed buyers for $217M plus as much as $35M in potential contingent payments based on the number of wells spud by the buyer on the assets over the next four years.</li>     <li>WRD also agrees to acquire producing and non-producing properties in Lee County, Tex., from an undisclosed seller for $19M.</li>     <li>The company also provides an <a href=\"https://seekingalpha.com/pr/17071379-wildhorse-resource-development-corporation-announces-year-end-2017-reserves-operational\" target=\"_blank\">operational update</a>, which says it increased proved reserves by 198% to 454.3M boe at year-end 2017 and PV-10 of proved reserves by 372% to $3.54B at year-end 2017 from $750M at year-end 2016.</li>     <li>WRD projects 2018 total production of 53K-56K boe/day, representing growth of 80% Y/Y at the midpoint of guidance, operating an average of 4.8 drilling rigs in the Eagle Ford and Austin Chalk in 2018; estimated 2018 drilling and completion capex is $700M-$800M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330175\" data-linked=\"WildHorse Resource to sell north Louisiana assets for $217M\" data-tweet=\"$WRD - WildHorse Resource to sell north Louisiana assets for $217M https://seekingalpha.com/news/3330175-wildhorse-resource-to-sell-north-louisiana-assets-for-217m?source=tweet\" data-url=\"https://seekingalpha.com/news/3330175-wildhorse-resource-to-sell-north-louisiana-assets-for-217m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330173\" data-ts=\"1518446532\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSCO\" target=\"_blank\">CSCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330173-ciscoplus-3-nomura-sees-16-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cisco +3% as Nomura sees 16% upside</a></h4><ul>   <li>Cisco Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CSCO' title='Cisco Systems, Inc.'>CSCO</a>) is a top gainer this morning, <font color='green'>up 3%</font>, as Nomura upgrades shares to Buy.</li>    <li>The firm raised its price target to $46 from $33; that's 16% upside from Friday's close and and 13% from here.</li>    <li>Meanwhile, RBC Capital has raised its price target to $44.</li>    <li>Shares have appreciated 29% over the past 12 months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330173\" data-linked=\"Cisco +3% as Nomura sees 16% upside\" data-tweet=\"$CSCO - Cisco +3% as Nomura sees 16% upside https://seekingalpha.com/news/3330173-ciscoplus-3-nomura-sees-16-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3330173-ciscoplus-3-nomura-sees-16-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330171\" data-ts=\"1518446262\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WUBA\" target=\"_blank\">WUBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330171-58-complus-1_5-on-analyst-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">58.com +1.5% on analyst upgrade</a></h4><ul><li>        CLSA <a href=\"https://www.streetinsider.com/Upgrades/CLSA+Upgrades+58.+com+Inc+%28WUBA%29+to+Buy/13796489.html\" target=\"_blank\">upgrades</a> 58.com (NYSE:<a href='https://seekingalpha.com/symbol/WUBA' title='58.com Inc.'>WUBA</a>) from Outperform to Buy.</li><li>               Latest analyst <a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=WUBA:NYQ\" target=\"_blank\">recommendations</a>: 5 Buy, 8 Outperform, 6 Hold, and 1 Underperform.&nbsp;</li><li>               Median price target: $82.50.&nbsp;</li><li>               58.com shares are&nbsp;<font color='green'>up 1.5%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3330171\" data-linked=\"58.com +1.5% on analyst upgrade\" data-tweet=\"$WUBA - 58.com +1.5% on analyst upgrade https://seekingalpha.com/news/3330171-58-complus-1_5-on-analyst-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3330171-58-complus-1_5-on-analyst-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330168\" data-ts=\"1518445760\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSC-OLD\" target=\"_blank\">SSC-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330168-seven-stars-cloudplus-5_6-alongside-ats-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seven Stars Cloud +5.6% alongside ATS deal</a></h4><ul>   <li>Seven Stars Cloud (NASDAQ:<a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>) is <font color='green'>up 5.6%</font> premarket alongside an announcement that its <a href=\"https://seekingalpha.com/pr/17071872-seven-stars-cloud-announces-new-global-business-initiative-newly-rebranded-optimized-trading\" target=\"_blank\">Next Gen X</a> technology will power the blockchain-based alternative trading system at the Delaware Board of TRade.</li>    <li>It adds that it's in the process of finalizing its own alternative trading system.</li>    <li>That will offer a \"plug and play\" solution to its Global Partners Trading Network to expand volume through targeted alternative trading systems, including DBOT.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330168\" data-linked=\"Seven Stars Cloud +5.6% alongside ATS deal\" data-tweet=\"$SSC-OLD - Seven Stars Cloud +5.6% alongside ATS deal https://seekingalpha.com/news/3330168-seven-stars-cloudplus-5_6-alongside-ats-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3330168-seven-stars-cloudplus-5_6-alongside-ats-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330167\" data-ts=\"1518445542\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330167-pareteumplus-4_8-after-chairman-outlines-2018-start\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum +4.8% after chairman outlines 2018 start</a></h4><ul>   <li>Pareteum (NYSEMKT:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) is <font color='green'>up 4.8%</font> premarket following on a <a href=\"https://seekingalpha.com/pr/17071577-pareteum-issues-chairman-update-letter\" target=\"_blank\">letter from its chairman</a> outlining its start to 2018.</li>    <li>In January alone, writes Hal Turner, the company signed $20.4M in new contracts around the world, and added $15.2M to a now record-high $162M backlog (which was $60M last June). Turner says he expects the pace to accelerate this year.</li>    <li>Cash balance rose to $15.6M as of Jan. 31, he notes, thanks to nearly zero operating cash burn, thanks in part to share appreciation that prompted voluntary exercise of warrants.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330167\" data-linked=\"Pareteum +4.8% after chairman outlines 2018 start\" data-tweet=\"$TEUM - Pareteum +4.8% after chairman outlines 2018 start https://seekingalpha.com/news/3330167-pareteumplus-4_8-after-chairman-outlines-2018-start?source=tweet\" data-url=\"https://seekingalpha.com/news/3330167-pareteumplus-4_8-after-chairman-outlines-2018-start\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330166\" data-ts=\"1518445527\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMP\" target=\"_blank\">ADMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330166-fda-accepts-adamis-pharmas-application-for-low-dose-symjepi-action-date-september-3-shares-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Adamis Pharma&#39;s application for low-dose Symjepi, action date September 3; shares up 1% premarket</a></h4><ul><li>Adamis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corp.'>ADMP</a>) is up&nbsp;<font color='green'>1%&nbsp;</font>premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17071803-adamis-pharmaceuticals-announces-fda-acceptance-review-supplemental-new-drug-application-low\" target=\"_blank\">announcement </a>that the FDA has accepted for review its marketing application for low-dose Symjepi (epinephrine) for the emergency treatment of allergic reactions in patients weighing 33 - 65 pounds. The current version is approved for patients weighing at least 66 pounds.</li><li>The agency's action date is September 3.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330166\" data-linked=\"FDA accepts Adamis Pharma&#39;s application for low-dose Symjepi, action date September 3; shares up 1% premarket\" data-tweet=\"$ADMP - FDA accepts Adamis Pharma&#39;s application for low-dose Symjepi, action date September 3; shares up 1% premarket https://seekingalpha.com/news/3330166-fda-accepts-adamis-pharmas-application-for-low-dose-symjepi-action-date-september-3-shares-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3330166-fda-accepts-adamis-pharmas-application-for-low-dose-symjepi-action-date-september-3-shares-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330164\" data-ts=\"1518445392\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMBR\" target=\"_blank\">AMBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330164-premarket-gainers-of-9-05-02-12-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (02/12/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/AMBR' title='Amber Road, Inc.'>AMBR</a> <font color='green'>+48%</font>.</li><li><a href='https://seekingalpha.com/symbol/DARE' title='Dare Bioscience, Inc.'>DARE</a> <font color='green'>+46%</font>.</li><li><a href='https://seekingalpha.com/symbol/CSRA' title='CSRA Inc.'>CSRA</a> <font color='green'>+32%</font>.</li><li><a href='https://seekingalpha.com/symbol/EMAN' title='eMagin Corporation'>EMAN</a> <font color='green'>+28%</font>&nbsp;as Apple <a href=\"https://seekingalpha.com/news/3330149-apple-updating-software-upgrade-schedule-emagin-plus-24-percent-apple-investment\" target=\"_blank\">updating</a> software upgrade schedule.</li><li><a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a> <font color='green'>+20%</font>&nbsp;on patent <a href=\"https://seekingalpha.com/pr/17071707-finjan-symantec-entered-confidential-term-sheet\" target=\"_blank\">infringement&nbsp;</a>retrial&nbsp;against Blue Coat Systems.</li><li><a href='https://seekingalpha.com/symbol/HGSH' title='China HGS Real Estate, Inc.'>HGSH</a> <font color='green'>+18%</font>&nbsp;on Q1 <a href=\"https://seekingalpha.com/news/3330095-china-hgs-real-estate-reports-q1-results\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/AQMS' title='Aqua Metals'>AQMS</a> <font color='green'>+15%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17071700-aqua-metals-provides-company-update\" target=\"_blank\">developing</a> a solution to address a condition described as &ldquo;sticky lead&rdquo;.</li><li><a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a> <font color='green'>+16%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/pr/17071658-iconix-brand-group-announces-private-exchange-approximately-110-million-convertible-notes\" target=\"_blank\">agreements</a> with holders of approximately $110M principal amount of the 1.5% convertible notes due March 2018.</li><li><a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a> <font color='green'>+12%</font>.</li><li><a href='https://seekingalpha.com/symbol/COLL' title='Collegium Pharmaceutical'>COLL</a> <font color='green'>+10%</font>&nbsp;as Purdue's <a href=\"https://seekingalpha.com/news/3330142-purdues-retrenchment-opioid-promotion-buoys-collegium-14-percent-premarket\" target=\"_blank\">retrenchment</a> from opioid promotion.</li><li><a href='https://seekingalpha.com/symbol/RNN' title='Rexahn Pharmaceuticals Inc'>RNN</a> <font color='green'>+7%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17071603-rexahn-reports-data-ongoing-phase-2a-clinical-trial-rxminus-3117-advanced-bladder-cancer\" target=\"_blank\">updating</a> safety and efficacy data from the ongoing Phase 2a clinical trial of RX-3117 in advanced urothelial (bladder) cancer.</li><li><a href='https://seekingalpha.com/symbol/NOG' title='Northern Oil & Gas, Inc'>NOG</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3330019-moviepass-promos-7_95-monthly-plan-along-fandor-streaming\" target=\"_blank\">promos</a> of $7.95 monthly plan along with Fandor streaming.</li><li><a href='https://seekingalpha.com/symbol/NXTD' title='NXT-ID Inc.'>NXTD</a> <font color='green'>+5%</font>.</li><li><a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a> <font color='green'>+6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3330157-premarket-analyst-action-healthcare\" target=\"_blank\">positive</a> analyst action.</li><li><a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='green'>+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330164\" data-linked=\"Premarket Gainers as of 9:05 am (02/12/2018)\" data-tweet=\"$AMBR $AMBR $DARE - Premarket Gainers as of 9:05 am (02/12/2018) https://seekingalpha.com/news/3330164-premarket-gainers-of-9-05-02-12-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3330164-premarket-gainers-of-9-05-02-12-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330163\" data-ts=\"1518445000\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DARE\" target=\"_blank\">DARE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330163-dar-bioscience-up-37-premarket-on-license-deal-for-fsad-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Daré Bioscience up 37% premarket on license deal for FSAD candidate</a></h4><ul><li>Thinly traded nano cap&nbsp;Dar&eacute; Bioscience (NASDAQ:<a href='https://seekingalpha.com/symbol/DARE' title='Dare Bioscience, Inc.'>DARE</a>) is up&nbsp;<font color='green'>37%</font>&nbsp;premarket on increased volume in apparent response to its <a href=\"https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138468439\" target=\"_blank\">announcement </a>that it has licensed a topical cream (SST-6007) from Strategic Science &amp; Technologies for the potential treatment of women with female sexual arousal disorder &#40;FSAD&#41;.</li><li>The active ingredient in SST-6007 is sildenafil, the active ingredient in Pfizer's Viagra.</li><li>SST-6607 demonstrated an increase in blood flow to vaginal tissue in a Phase 2 study in women with FSAD. The company plans to pursue U.S. approval via the abbreviated 505(b)(2) pathway which allows the inclusion of data generated by others.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330163\" data-linked=\"Daré Bioscience up 37% premarket on license deal for FSAD candidate\" data-tweet=\"$DARE - Daré Bioscience up 37% premarket on license deal for FSAD candidate https://seekingalpha.com/news/3330163-dar-bioscience-up-37-premarket-on-license-deal-for-fsad-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3330163-dar-bioscience-up-37-premarket-on-license-deal-for-fsad-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330162\" data-ts=\"1518444825\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNJN\" target=\"_blank\">FNJN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330162-finjanplus-20-after-symantec-term-sheet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finjan +20% after Symantec term sheet</a></h4><ul><li>        Finjan (NASDAQ:<a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a>) <a href=\"https://seekingalpha.com/pr/17071707-finjan-symantec-entered-confidential-term-sheet\" target=\"_blank\">announces</a> that its patent infringement retrial against Blue Coat System has been vacated</li><li>        Finjan and Blue Coat&rsquo;s parent, Symantec (NASDAQ:<a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a>), have entered a confidential term sheet that&rsquo;s expected to be finalized by no later than February 28.</li><li>               Finjan shares are&nbsp;<font color='green'>up 20.3%</font>.&nbsp;</li><li>               Symantec shares are&nbsp;<font color='green'>up 0.4%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3327888-cisco-cuts-stake-litigation-opponent-finjan-zero\" target=\"_blank\">Cisco cuts stake in litigation opponent Finjan to zero</a> (Feb. 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330162\" data-linked=\"Finjan +20% after Symantec term sheet\" data-tweet=\"$FNJN $FNJN $NLOK - Finjan +20% after Symantec term sheet https://seekingalpha.com/news/3330162-finjanplus-20-after-symantec-term-sheet?source=tweet\" data-url=\"https://seekingalpha.com/news/3330162-finjanplus-20-after-symantec-term-sheet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330159\" data-ts=\"1518444544\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXON\" target=\"_blank\">AXON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330159-premarket-losers-of-9-05-2-12-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (2/12/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a>&nbsp;<font color='red'>-19%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3330103-axovant-shakes-management-ceo-coo\" target=\"_blank\">announcing</a> changes to management team and Board of Directors.</li><li><a href='https://seekingalpha.com/symbol/SMI' title='Semiconductor Manufacturing International Corporation'>SMI</a>&nbsp;<font color='red'>-6%</font>&nbsp;on analyst <a href=\"https://seekingalpha.com/news/3330102-semi-manufacturing-minus-6-percent-analyst-downgrades\" target=\"_blank\">downgrades</a>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3330159\" data-linked=\"Premarket Losers as of 9:05 am (2/12/2018)\" data-tweet=\"$AXON $AXON-OLD $SMI - Premarket Losers as of 9:05 am (2/12/2018) https://seekingalpha.com/news/3330159-premarket-losers-of-9-05-2-12-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3330159-premarket-losers-of-9-05-2-12-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330151\" data-ts=\"1518443848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBVX\" target=\"_blank\">MBVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330151-mabvaxs-mvtminus-5873-shows-positive-action-in-first-line-pancreatic-cancer-shares-ahead-17\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MabVax&#39;s MVT-5873 shows positive action in first-line pancreatic cancer; shares ahead 17% premarket</a></h4><ul><li>MabVax Therapeutics (<a href='https://seekingalpha.com/symbol/MBVX' title='MABVAX THERAPEUTICS HLDGS'>OTCPK:MBVX</a>) is up&nbsp;<font color='green'>17%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17071467-mabvax-therapeutics-announces-positive-interim-data-expanded-cohort-phase-1-trial-evaluating\" target=\"_blank\">announcement </a>of positive interim results from an open-label <a href=\"https://clinicaltrials.gov/ct2/show/NCT02672917?term=NCT+02672917&amp;rank=1\" target=\"_blank\">Phase 1 clinical trial</a> assessing MVT-5873, combined with standard-of-care chemo, in newly diagnosed patients with pancreatic cancer and other CA19-9 malignancies.</li><li>At the dose tested, all six patients showed meaningful reductions in tumor volume, including four partial responders and two with stable disease. CA19-9 levels, a biomarker for pancreatic cancer, were significantly reduced in all subjects.</li><li>Enrollment is ongoing. The results will inform on the design and dose for a Phase 2 study.</li><li>MVT-5873 is a fully human monoclonal antibody (<a href=\"http://www.mabvax.com/humab-5b1.php\" target=\"_blank\">HuMab-5B1</a>) that was discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during an early-stage study at Memorial Sloan Kettering Cancer Center. The antibody targets an antigen expressed in more 90% of pancreatic cancers.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3271505-mabvaxs-therapeutic-antibody-mvtminus-5873-shows-treatment-effect-early-stage-pancreatic\" target=\"_blank\">MabVax's therapeutic antibody MVT-5873 shows treatment effect in early-stage pancreatic cancer study</a> (June 5, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330151\" data-linked=\"MabVax&#39;s MVT-5873 shows positive action in first-line pancreatic cancer; shares ahead 17% premarket\" data-tweet=\"$MBVX $MBVXQ - MabVax&#39;s MVT-5873 shows positive action in first-line pancreatic cancer; shares ahead 17% premarket https://seekingalpha.com/news/3330151-mabvaxs-mvtminus-5873-shows-positive-action-in-first-line-pancreatic-cancer-shares-ahead-17?source=tweet\" data-url=\"https://seekingalpha.com/news/3330151-mabvaxs-mvtminus-5873-shows-positive-action-in-first-line-pancreatic-cancer-shares-ahead-17\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330149\" data-ts=\"1518443644\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330149-apple-updating-software-upgrade-schedule-emaginplus-24-on-apple-investment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple updating software upgrade schedule; eMagin +24% on Apple investment</a></h4><ul><li>        Bloomberg <a href=\"https://www.bloomberg.com/news/articles/2018-02-12/how-apple-plans-to-root-out-bugs-revamp-iphone-software\" target=\"_blank\">offers a preview</a> of Apple&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) fall software upgrade including the fact that some major features were delayed as Apple updates how the company develops new products. &nbsp;</li><li>        Key quote: &ldquo;Instead of keeping engineers on a relentless annual schedule and cramming features into a single update, Apple will start focusing on the next two years of updates for its iPhone and iPad operating system, according to people familiar with the change.&rdquo;</li><li>               OLED investment: Apple and LG contributed to a <a href=\"https://techcrunch.com/2018/02/12/apple-joins-lg-and-valve-investing-up-to-10m-in-oled-display-maker-emagin/?ncid=rss&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+Techcrunch+%28TechCrunch%29\" target=\"_blank\">$10.6M investing round</a> in OLED miniature display maker eMagin (NYSEMKT:<a href='https://seekingalpha.com/symbol/EMAN' title='eMagin Corporation'>EMAN</a>).&nbsp;</li><li>               Other contributors were Valve, Stillwater Holdings, and VR entertainment company Immerex.&nbsp;</li><li>               The startup created a new type of VR headset display that can provide a sharper image using a denser layout of lines instead of pixels.&nbsp;</li><li>               EMagin shares are&nbsp;<font color='green'>up 24%</font>&nbsp;premarket.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3330149\" data-linked=\"Apple updating software upgrade schedule; eMagin +24% on Apple investment\" data-tweet=\"$AAPL $AAPL $EMAN - Apple updating software upgrade schedule; eMagin +24% on Apple investment https://seekingalpha.com/news/3330149-apple-updating-software-upgrade-schedule-emaginplus-24-on-apple-investment?source=tweet\" data-url=\"https://seekingalpha.com/news/3330149-apple-updating-software-upgrade-schedule-emaginplus-24-on-apple-investment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}